ibuprofen has been researched along with Osteoarthritis in 219 studies
Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine
Osteoarthritis: A progressive, degenerative joint disease, the most common form of arthritis, especially in older persons. The disease is thought to result not from the aging process but from biochemical changes and biomechanical stresses affecting articular cartilage. In the foreign literature it is often called osteoarthrosis deformans.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Insured patients with a history of osteoarthritis or back pain and receiving ibuprofen, other ns-NSAIDs, COX-2i or paracetamol between 1 November, 2019 and 31 January, 2020 (study enrolment window 1) or between 1 February, 2020 and 31 October, 2020 (study enrolment window 2)." | 9.41 | Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study. ( Argyriou, G; Brash, JT; Driessen, S; Prieto-Alhambra, D; Reich, C; Seager, S; Turkmen, C; Varrassi, G; Xie, J, 2023) |
| "A 4-week, multicentre, randomised, double-blind study has compared the effects of lumiracoxib 100 mg once daily (od) (n = 394) and ibuprofen 600 mg three times daily (tid) (n = 393) on ambulatory BP in osteoarthritis (OA) patients with controlled hypertension." | 9.14 | The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents. ( Krammer, G; Lheritier, K; MacDonald, TM; Richard, D, 2010) |
| " To examine whether lumiracoxib 100 mg once daily would result in lower 24-h mean systolic ambulatory blood pressure than ibuprofen 600 mg three times daily in osteoarthritis patients with controlled hypertension, a 4-week, randomized, double-blind, parallel-group study was conducted in 79 centres in nine countries." | 9.13 | Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. ( Krammer, G; Lheritier, K; Littlejohn, TW; MacDonald, TM; Rebuli, R; Reginster, JY; Richard, D, 2008) |
| "To compare the effects of continuous and intermittent celecoxib treatment in patients with knee or hip osteoarthritis in flare." | 9.12 | A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip. ( De Clerck, L; De Keyser, F; Geusens, P; Hauzeur, JP; Luyten, FP; Malaise, M; Mathy, L; Raeman, F; Van den Bosch, F; Vander Mijnsbrugge, D; Westhovens, R, 2007) |
| "We performed a placebo-controlled, randomized study to address whether celecoxib or ibuprofen undermines the functional range of inhibition of platelet cyclooxygenase (COX)-1 activity by aspirin in patients with osteoarthritis and stable ischemic heart disease." | 9.12 | Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. ( Capone, ML; D'Amelio, E; De Caterina, R; Grana, M; Patrignani, P; Patrono, C; Price, TS; Renda, G; Sacchetta, D; Santarelli, F; Sciulli, MG; Tacconelli, S; Zimarino, M; Zurro, M, 2006) |
| "To determine the cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib." | 9.12 | Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. ( Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW, 2007) |
| "We compared the efficacy of etoricoxib 30 mg to placebo and ibuprofen 2400 mg for the treatment of osteoarthritis (OA) of the hip and knee." | 9.12 | A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. ( Berrocal, A; Boice, JA; Cichanowitz, N; Fidelholtz, JL; Ko, A; Littlejohn, TW; Miranda, P; Puopolo, A; Reicin, AS, 2007) |
| "To compare efficacy of pain syndrome relief in osteoarthrosis at conventional administration and ultraphonophoresis of ibuprofen (nurofen gel), we applied ultraphonophoresis of 5% gel nurofen to affected joints of 20 patients of the study group (twice a day with a 5-6 hour interval; the third time the gel was applied locally in the evening)." | 9.12 | [Efficacy of ibuprofen (nurofen gel) ultraphonophoresis for pain relief in osteoarthrosis]. ( Serikov, NP, 2007) |
| "In patients with OA, lumiracoxib 200 mg or 400 mg qd was associated with a significantly lower risk of gastroduodenal ulceration than ibuprofen 800 mg tid, and was similar to celecoxib 200 mg qd." | 9.11 | Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. ( Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P, 2004) |
| "To directly compare the efficacy and safety of etoricoxib, 30 mg once daily, ibuprofen, 800 mg 3 times daily, and placebo for treatment of osteoarthritis (OA) of the hip and knee." | 9.11 | Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. ( Aversano, ML; Boice, JA; Ko, A; Murphy, FT; Reicin, AS; Sheldon, EA; Wiesenhutter, CW; Wittmer, BA, 2005) |
| " This study sought to evaluate dyspepsia-related health in osteoarthritis (OA) and rheumatoid arthritis (RA) patients taking valdecoxib compared with patients taking nonspecific NSAIDs." | 9.11 | Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis. ( Goldstein, JL; Mayne, TJ; Rabeneck, L; Rublee, DA; Vu, A, 2005) |
| "Because in vitro studies have shown that nimesulide not only preferentially inhibits COX-2 but also reduces the action/release of pro-inflammatory cytokines, down-regulates the synthesis and/or activity of collagenase(s), and releases reactive oxygen species and other toxic substances from neutrophils, this study investigated whether nimesulide and ibuprofen could affect levels of biochemical markers of joint inflammation and collagen catabolism in patients with flare-up of knee or hip osteoarthritis." | 9.11 | Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis. ( Bevilacqua, M; Devogelaer, JP; Famaey, JP; Manicourt, DH; Righini, V, 2005) |
| " Overall, the data indicate that administration of valdecoxib offers similar efficacy for the treatment of osteoarthritis but improved upper-gastrointestinal safety compared with the conventional NSAIDs, ibuprofen and diclofenac, based on the significantly lower incidence of gastroduodenal ulcers detected by endoscopy." | 9.10 | Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. ( Agrawal, NM; Kent, JD; Recker, DP; Sikes, DH; Verburg, KM; Zhao, WW, 2002) |
| " We hypothesized that COX-2-specific inhibition with rofecoxib (25 mg once daily) in the treatment of patients with osteoarthritis would cause fewer gastroduodenal ulcers than an equally effective dose of ibuprofen (800 mg 3 times a day), a nonspecific COX inhibitor." | 9.09 | A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. ( Bath, R; Bolognese, J; Harper, S; Johanson, J; Laine, L; Quan, H; Schwartz, H; Simon, T; Stern, S, 1999) |
| "Ginger extract was compared to placebo and Ibuprofen in patients with osteoarthritis of the hip or knee in a controlled, double blind, double dummy, cross-over study with a wash-out period of one week followed by three treatment periods in a randomized sequence, each of three weeks duration." | 9.09 | A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. ( Andersen, LA; Barslev, J; Bliddal, H; Christensen, K; Ibfelt, HH; Jensen, ON; Rosetzsky, A; Schlichting, P; Weidner, MS, 2000) |
| "Both doses of rofecoxib demonstrated efficacy clinically comparable with ibuprofen as assessed by 3 primary end points (pain walking on a flat surface [Western Ontario and McMaster Universities Osteoarthritis Index], patient global assessment of response to therapy, and investigator global assessment of disease status) according to predefined comparability criteria." | 9.09 | A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. ( Bolognese, J; Castaneda, O; Daniels, B; Day, R; Ehrich, E; Helgetveit, KB; Kress, B; Krupa, D; Luza, A; Morrison, B; Nahir, M; Seidenberg, B; Strusberg, A, 2000) |
| "The pharmacokinetic interactions between BAY 12-9566 and two nonsteroidal anti-inflammatory drugs (NSAIDs), naproxen and ibuprofen, were investigated in osteoarthritis (OA) patients." | 9.09 | Pharmacokinetics, safety, and tolerability of BAY 12-9566 and nonsteroidal anti-inflammatory agents (naproxen, ibuprofen) during coadministration in patients with osteoarthritis. ( Agarwal, V; Liu, P; Shah, A; Sundaresan, P; Woodruff, M, 2001) |
| "To compare the treatment potential of glucosamine sulfate (GS) and ibuprofen in patients diagnosed with temporomandibular joint (TMJ) osteoarthritis (OA)." | 9.09 | Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: a randomized double blind controlled 3 month clinical trial. ( Major, PW; Prasad, NG; Thie, NM, 2001) |
| "A double-blind therapeutic investigation was performed on 178 Chinese patients suffering from osteoarthritis of the knee randomized into two groups, one treated for 4 weeks with glucosamine sulfate (GS, CAS 29031-19-4, Viartril-S) at the daily dose of 1,500 mg and the other with ibuprofen (IBU, CAS 15687-27-1) at the daily dose of 1,200 mg." | 9.08 | Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. ( Gao, SN; Giacovelli, G; Qiu, GX; Rovati, L; Setnikar, I, 1998) |
| "The duration of action of sustained-release ibuprofen ('Brufen Retard') was investigated in a 14-day double-blind study involving 14 osteoarthritis and 10 rheumatoid arthritis patients." | 9.07 | Investigation into the duration of action of sustained-release ibuprofen in osteoarthritis and rheumatoid arthritis. ( Fernandes, L; Jenkins, R, 1994) |
| "The efficacy of nabumetone was compared with that of diclofenac, naproxen, ibuprofen, and piroxicam in patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in a randomized, controlled, open-label, multicenter trial." | 9.07 | Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Lister, BJ; Poland, M, 1993) |
| "The pharmacokinetics of the enantiomers of ibuprofen have been investigated following oral administration of 300 or 600 mg of racemic ibuprofen four times daily to 45 patients with osteoarthritis." | 9.07 | Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients. ( Bradley, JD; Hall, SD; Kalasinski, LA; Rudy, AC; Ryan, SI; Xiaotao, Q, 1992) |
| "Stereoselective pharmacokinetic measurements of the active enantiomer, S-ibuprofen, were correlated with clinical response in 45 participants in a randomized double blinded 4 week comparison of ibuprofen, 1200 or 2400 mg/day, for treatment of hip or knee osteoarthritis." | 9.07 | Correlation of serum concentrations of ibuprofen stereoisomers with clinical response in the treatment of hip and knee osteoarthritis. ( Bradley, JD; Brandt, KD; Brater, DC; Hall, SD; Kalasinski, LA; Katz, BP; Rudy, AC; Ryan, SI, 1992) |
| "In a randomized, double-blind trial, 184 patients with chronic knee pain due to osteoarthritis were given either 2400 or 1200 mg of ibuprofen per day or 4000 mg of acetaminophen per day." | 9.07 | Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. ( Bradley, JD; Brandt, KD; Kalasinski, LA; Katz, BP; Ryan, SI, 1991) |
| "3,672 patients with activated osteoarthritis were treated for 20 days with daily doses of 1,800 to 2,400 mg ibuprofen (Anco)." | 9.06 | ["Morning type" and "evening type" in activated osteoarthritis. Analysis and practice-related conclusions of an open, multicenter study with ibuprofen]. ( Karrasch, KF; Moerchel, J, 1989) |
| "Twenty-eight patients with osteoarthritis participated in a prospective, double-blind, cross-over study to compare the safety and efficacy of a new combination analgesic containing ibuprofen 200 mg, paracetamol 250 mg and codeine phosphate 10 mg per tablet (Myprodol; Rio Ethicals) with a standard treatment regimen (ibuprofen 200 mg per tablet)." | 9.06 | Comparison of a standard ibuprofen treatment regimen with a new ibuprofen/paracetamol/codeine combination in chronic osteo-arthritis. ( van Vuren, JP; Vlok, GJ, 1987) |
| "Despite a wide range of study designs, a multiplicity of international trials of diclofenac in osteoarthritis have disclosed similar results." | 9.06 | International experiences with diclofenac in osteoarthritis. ( Altman, R, 1986) |
| "One hundred forty-one subjects with osteoarthritis completed this double-blind, multicenter, crossover trial comparing four nonsteroidal anti-inflammatory (NSAI) agents after single-blind aspirin stabilization." | 9.05 | Four-way, multicenter, crossover trial of ibuprofen, fenoprofen calcium, naproxen, and tolmetin sodium in osteoarthritis: comparative clinical profiles. ( Caldwell, JR; Crain, D; Hoffmeister, RT; Kantrowitz, F; Lloyd, RJ; Nussdorf, RT; Repice, MR; Schmid, FR, 1983) |
| "Two multi-centre studies were carried out in general practice comparing tiaprofenic acid ('Surgam') with five other non-steroidal anti-inflammatory agents (ibuprofen, indomethacin, naproxen, piroxicam and benoxaprofen), one in rheumatoid arthritis and one in osteoarthritis." | 9.05 | A multi-centre study of tiaprofenic acid ('Surgam') and five comparative drugs in rheumatoid arthritis and osteoarthritis in general practice. ( Clarke, TK; Mungavin, JM, 1983) |
| "43 patients with osteoarthritis of the knee and/or hip(s) were treated with suprofen 800 mg/day or ibuprofen 1,600 mg/day for 14 days." | 9.05 | Comparison of suprofen and ibuprofen in the treatment of pain secondary to osteoarthritis. ( Schuermans, Y, 1983) |
| "A total of 226 patients with osteoarthritis of the hip, knee or spine was entered into a general practice, multi-centre, crossover study of 500 mg naproxen twice daily and 400 mg ibuprofen 3-times daily." | 9.05 | A study of naproxen and ibuprofen in patients with osteoarthritis seen in general practice. The Manchester General Practitioner Group. ( , 1984) |
| "One hundred and thirty-one patients with osteoarthritis of the knee or hip entered a comparative trial of sustained release (SR) ibuprofen ('Fenbid') and piroxicam ('Feldene')." | 9.05 | Is sustained-release ibuprofen as effective as piroxicam? A comparison in patients with osteoarthritis. ( Cornhill, J; Rowley-Jones, D, 1984) |
| "A study was carried out in 30 elderly patients, aged between 65 and 89 years, with osteoarthritis of the hip and/or knee joints to assess the efficacy and tolerance of sulindac compared with ibuprofen." | 9.05 | A study of sulindac versus ibuprofen in elderly patients with osteoarthritis. ( Admani, AK; Verma, S, 1983) |
| "A double-blind within-patient crossover trial compared the new nonsteroidal antiinflammatory agent benoxaprofen with ibuprofen in the treatment of osteoarthritis in 31 patients." | 9.05 | Benoxaprofen in the treatment of osteoarthritis--a comparison with ibuprofen. ( Grahame, R; Highton, J, 1980) |
| "A total of 120 general practice patients with osteoarthritis of the knee or hip received either benoxaprofen 600 mg mane or ibuprofen 400 mg tid for 4 months in a double-blind, parallel trial." | 9.05 | A comparative study of benoxaprofen and ibuprofen in osteoarthritis in general practice. ( Glynne, A; Tyson, VC, 1980) |
| "Benoxaprofen was compared to aspirin or to ibuprofen in 2 28-wk multiclinic double-blind trials in patients with symptomatic osteoarthritis of the knees or hips." | 9.05 | Long-term treatment of symptomatic osteoarthritis with benoxaprofen. Double-blind comparison with aspirin and ibuprofen. ( Alarcon-Segovia, D, 1980) |
| "A double-blind crossover study compared sodium meclofenamate (300 mg daily) and ibuprofen (900 mg daily) in thirty patients with osteoarthritis." | 9.05 | Short-term treatment of osteoarthritis: a comparison of sodium meclofenamate and ibuprofen. ( Accardo, S; Cimmino, MA; Cutolo, M; Samantà, E, 1982) |
| "Thirty-two elderly patients with symptomatic osteoarthritis predominantly of the hip and/or knee joints were randomly treated on an open basis for 12 weeks with either 400 mg sulindac or 1200 mg ibuprofen per day." | 9.05 | A randomized comparison between sulindac and ibuprofen in osteoarthritis of the aged. ( Ghosh, AK; Rastogi, AK, 1981) |
| "A randomized double-blind multicentre clinical trial was carried out to verify the effectiveness and tolerance of S-adenosylmethionine (SAMe) versus ibuprofen in 150 patients with hip and/or knee osteoarthritis." | 9.05 | Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis. ( Cherie-Ligniere, G; Colombo, B; Giordano, M; Glorioso, S; Leardini, G; Marcolongo, R; Mattara, L; Mazzi, A; Passeri, M; Todesco, S, 1985) |
| "In a double-blind, multiclinic study, 437 patients with osteoarthritis were treated sequentially with ibuprofen, 1,800 mg/day, and placebo, or with aspirin, 3,600 mg/day, and placebo." | 9.04 | Ibuprofen in osteoarthritis. ( Brooks, CD; Donaldson, MS; Giansiracusa, JE; Koonce, ML; Lefton, TE; Ruoff, GE, 1977) |
| "A randomized double-blind study in ambulatory patients with osteoarthritis of hip and/or knee was conducted, comparing the efficacy and safety of diflunisal 500 mg daily with ibuprofen 1200 mg daily, and a period of 8 weeks." | 9.04 | A comparative clinical trial of diflunisal and ibuprofen in the control of pain in osteoarthritis. ( Keet, JG, 1979) |
| "Flurbiprofen and ibuprofen, two propionic acid derivatives with anti-inflammatory and analgesic activity, were compared in a double-blind multiclinic study in 195 patients with osteoarthritis of the peripheral joints." | 9.04 | Response of osteoarthritis to ibuprofen or flurbiprofen. ( Ehrlich, GE; Giansiracusa, J; Gray, J; Mena, HR; Ward, J, 1976) |
| "In a double-blind multiclinic trial, a new nonsteroidal anti-inflammatory agent (ibuprofen) was compared with an established therapeutic agent (phenylbutazone-alka) for the treatment of osteoarthritis." | 9.04 | Ibuprofen versus buffered phenylbutazone in the treatment of osteoarthritis: double-blind trial. ( Donovan, JF; Hearron, MS; Levi, L; Moxley, TE; Royer, GL, 1975) |
| "Oxaceprol, a derivative of l-proline, is an established drug for managing osteoarthritis (OA) with better safety profile than non-steroidal anti-inflammatory drugs (NSAIDs)." | 9.01 | A systematic review and meta-analysis of oxaceprol in the management of osteoarthritis: An evidence from randomized parallel-group controlled trials. ( Bhate, J; Durg, S; Lobo, M; Rao, G; Venkatachalam, L, 2019) |
| "Although anti-inflammatory doses of ibuprofen are very effective in treating the signs and symptoms of osteoarthritis (OA), they come with an increased risk for gastrointestinal damage which can limit their use and decrease patient adherence to therapy." | 8.90 | Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. ( Bello, AE; Grahn, AY; Holt, RJ; Kent, JD; Rice, P, 2014) |
| "The aim of this meta-analysis based on the literature was to gather all evidence of randomized clinical trials to assess the efficacy of adenosylmethionine (SAM) and oxaceprol in the treatment of osteoarthritis." | 8.81 | [Meta-analysis of the efficacy of adenosylmethionine and oxaceprol in the treatment of osteoarthritis]. ( Lasek, R; Victor, N; Witte, S, 2002) |
| "To determine the effectiveness of oral glucosamine with ibuprofen for the relief of joint pain in osteoarthritis a mini-review (Griffiths, 2002) of double-blind randomized controlled trials comparing the two was undertaken." | 8.81 | Glucosamine therapy compared to ibuprofen for joint pain. ( Griffiths, P; Ruane, R, 2002) |
| " Published data indicate that diclofenac 75 to 150mg daily (25 to 50mg 3 times daily) is comparable in efficacy with ordinary aspirin 3 to 5g daily and indomethacin 75 to 150mg daily in rheumatoid arthritis and with indomethacin in osteoarthritis." | 8.76 | Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. ( Avery, GS; Brogden, RN; Heel, RC; Pakes, GE; Speight, TM, 1980) |
| "Nonsteroidal antiinf lammatory drugs (NSAIDs) remain the mainstay of the pharmacologic management for relieving osteoarthritis pain, and low-dose aspirin is often prescribed to osteoarthritis patients who are at high risk of cardiovascular disease (CVD)." | 8.31 | Interactions of Nonsteroidal Antiinflammatory Drugs and Aspirin and Risk of Cardiovascular Disease in Patients With Osteoarthritis. ( Lane, NE; Lei, G; Li, X; Wei, J; Zeng, C; Zhang, Y, 2023) |
| "We identified randomised controlled trials (RCTs) of diclofenac with planned study duration of at least 4 weeks for the treatment of osteoarthritis (OA) from 'legacy' studies conducted by Novartis but not published in a peer reviewed journal or included in any previous pooled analyses." | 7.85 | Efficacy and safety of diclofenac in osteoarthritis: Results of a network meta-analysis of unpublished legacy studies. ( Andrew Moore, R; Chaves, RL; Guyot, P; Iqbal, A; Nixon, RM; Pandhi, S, 2017) |
| "The objectives of this study were (1) to fabricate ibuprofen-loaded porous microspheres (IBU/PMSs), (2) to evaluate the in vitro anti-inflammatory effects of the microspheres using LPS-induced inflammation in cultured synoviocytes, and (3) to evaluate the in vivo effect of the IBU/PMSs on the progression of monosodium iodoacetate (MIA)-induced osteoarthritis (OA) in a rat model." | 7.83 | Ibuprofen-loaded porous microspheres suppressed the progression of monosodium iodoacetate-induced osteoarthritis in a rat model. ( Kim, HJ; Kim, SE; Lee, JY; Park, JW; Park, K; Song, HR; Yun, YP, 2016) |
| "Single-tablet ibuprofen/famotidine is approved by the US Food and Drug Administration for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal (GI) ulcers in patients taking ibuprofen for those indications." | 7.79 | Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis. ( Holt, RJ; Johnson, KE; Kent, JD; Kuan, R; Malone, D; Peura, DA, 2013) |
| "A case of periorbital edema associated with separate courses of ibuprofen and naproxen is reported." | 7.76 | Periorbital edema associated with separate courses of ibuprofen and naproxen. ( Balas, M; Plakogiannis, R; Sinnett, M, 2010) |
| " To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 7.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
| "This study combined existing data to test the hypothesis that GI comedications and GI diagnostic procedures occur less frequently in osteoarthritis (OA) patients treated with rofecoxib compared with nonselective NSAIDs." | 7.71 | Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. ( Bolognese, JA; Harper, SE; Simon, TJ; Watson, DJ; Zhao, PL, 2001) |
| "The incidence of lower extremity edema (LEE) AEs was generally similar between rofecoxib 12." | 7.71 | A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. ( Bolognese, JA; Gertz, BJ; Krupa, D; Reicin, A; Sperling, RS, 2002) |
| "To analyze results of treatment of osteoarthritis (OA) with acetaminophen and the nonsteroidal antiinflammatory drugs (NSAID) through a patient survey." | 7.70 | Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. ( Callahan, LF; Cummins, P; Pincus, T; Swearingen, C, 2000) |
| " We compared the 3-month direct medical costs, including those associated with treating NSAID-induced adverse events, of nabumetone, ibuprofen, or ibuprofen plus misoprostol in 171 elderly patients with osteoarthritis." | 7.69 | Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol. ( Baker, AM; Bentkover, JD; Kaplan, H, 1994) |
| "Thirty-two elderly patients with symptomatic osteoarthritis, mainly of the hip and/or knee joints, were treated at random with either 400 mg sulindac or 1200 mg ibuprofen per day for 12 weeks." | 7.66 | Symptomatic osteoarthritis in the elderly: a comparative study of sulindac and ibuprofen. ( Ghosh, AK; Rastogi, AK, 1982) |
| "Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1." | 6.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| "Ibuprofen was also better tolerated than diclofenac sodium (100 mg/day), the latter being associated with gastrointestinal side effects in a significant proportion of patients." | 6.68 | Ibuprofen and diclofenac sodium in the treatment of osteoarthritis: a comparative trial of two once-daily sustained-release NSAID formulations. ( Baumgartner, H; Blum, W; Bruhin, A; Gallachi, G; Goldinger, G; Saxer, M; Schwarz, HA; Trost, H, 1996) |
| "Naproxen-treated patients experienced significantly (p < 0." | 6.67 | Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Eversmeyer, W; Jensen, CP; Poland, M, 1993) |
| "Carprofen is a propionic acid-derived NSAID that has anti-inflammatory, analgesic, and antipyretic activity." | 6.40 | Use of carprofen for the treatment of pain and inflammation in dogs. ( Fox, SM; Johnston, SA, 1997) |
| " The results of 28 comparative studies with ibuprofen in the treatment of osteoarthritis are classified in a synopsis." | 6.16 | [Statistical meta-analysis of multicenter clinical studies of ibuprofen with regard to cohort size]. ( Fischer, M; Haase, W, 1991) |
| "We can use from escin for the treatment of osteoarthritis as an anti-inflammatory agent in the latter but further studies to support the results from such a model are needed." | 5.48 | Evaluation of the effect of polyphenol of escin compared with ibuprofen and dexamethasone in synoviocyte model for osteoarthritis: an in vitro study. ( Hallajzadeh, J; Maghsoudi, H; Rezaeipour, M, 2018) |
| "Insured patients with a history of osteoarthritis or back pain and receiving ibuprofen, other ns-NSAIDs, COX-2i or paracetamol between 1 November, 2019 and 31 January, 2020 (study enrolment window 1) or between 1 February, 2020 and 31 October, 2020 (study enrolment window 2)." | 5.41 | Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study. ( Argyriou, G; Brash, JT; Driessen, S; Prieto-Alhambra, D; Reich, C; Seager, S; Turkmen, C; Varrassi, G; Xie, J, 2023) |
| " Given the low rates of events, at low or intermittent dosage without concurrent treatment, these 3 analgesics cannot be distinguished from each other or from background rates of serious GI toxicity." | 5.32 | Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis. ( Bruce, B; Fries, JF, 2003) |
| "To determine the relative risks of cardiovascular (CV), gastrointestinal (GI), and renal adverse events during long-term treatment with celecoxib, compared with ibuprofen and naproxen, in patients with osteoarthritis (OA) and patients with rheumatoid arthritis (RA)." | 5.27 | Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial. ( Bao, W; Berger, MF; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2018) |
| " Osteoarthritis or rheumatoid arthritis patients, needing ongoing NSAID treatment, were randomised to receive celecoxib 100-200 mg b." | 5.27 | Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial. ( Bao, W; Borer, JS; Graham, DY; Husni, ME; Libby, P; Lincoff, AM; Lüscher, TF; Nissen, SE; Solomon, DH; Stevens, T; Vargo, J; Walker, C; Wang, Q; Wisniewski, LM; Wolski, KE; Yeomans, ND, 2018) |
| "In this double-blind, randomized, multicentre non-inferiority CV-safety trial, 444 patients (mean age 62 ± 10 years, 54% female) with osteoarthritis (92%) or rheumatoid arthritis (8%) and evidence of or at increased risk for coronary artery disease received celecoxib (100-200 mg bid), ibuprofen (600-800 mg tid), or naproxen (375-500 mg bid) with matching placebos in a 1: 1: 1 allocation, to assess the effect on 24-h ambulatory BP after 4 months." | 5.24 | Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) ( Beckerman, B; Borer, JS; Davey, DA; Fayyad, R; Flammer, AJ; Graham, DY; Husni, ME; Iorga, D; Krum, H; Libby, P; Lincoff, AM; Lüscher, TF; Menon, V; Nissen, SE; Ruschitzka, F; Solomon, DH; Wisniewski, LM; Yeomans, ND, 2017) |
| "To carry out a randomized clinical trial to compare the effect of palmitoylethanolamide (PEA) versus ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), for pain relief in temporomandibular joint (TMJ) osteoarthritis or arthralgia." | 5.16 | Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain. ( Bartolucci, ML; Bonetti, GA; Bortolotti, F; Gatto, MR; Marini, I, 2012) |
| "We measured the urinary excretion of ATL in 24 patients with both ischaemic heart disease and osteoarthritis, chronically treated with aspirin and co-administered celecoxib 200 mg b." | 5.14 | Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors. ( De Caterina, R; Renda, G; Romano, M; Zurro, M, 2010) |
| "A 4-week, multicentre, randomised, double-blind study has compared the effects of lumiracoxib 100 mg once daily (od) (n = 394) and ibuprofen 600 mg three times daily (tid) (n = 393) on ambulatory BP in osteoarthritis (OA) patients with controlled hypertension." | 5.14 | The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents. ( Krammer, G; Lheritier, K; MacDonald, TM; Richard, D, 2010) |
| " To examine whether lumiracoxib 100 mg once daily would result in lower 24-h mean systolic ambulatory blood pressure than ibuprofen 600 mg three times daily in osteoarthritis patients with controlled hypertension, a 4-week, randomized, double-blind, parallel-group study was conducted in 79 centres in nine countries." | 5.13 | Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. ( Krammer, G; Lheritier, K; Littlejohn, TW; MacDonald, TM; Rebuli, R; Reginster, JY; Richard, D, 2008) |
| "To compare the effects of continuous and intermittent celecoxib treatment in patients with knee or hip osteoarthritis in flare." | 5.12 | A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip. ( De Clerck, L; De Keyser, F; Geusens, P; Hauzeur, JP; Luyten, FP; Malaise, M; Mathy, L; Raeman, F; Van den Bosch, F; Vander Mijnsbrugge, D; Westhovens, R, 2007) |
| "The cardiorenal safety database from the Celecoxib Long-term Arthritis Safety Study (CLASS) was analyzed to examine whether supratherapeutic doses of celecoxib are associated with decreased renal function and blood pressure (BP) effects compared with standard doses of diclofenac and ibuprofen in osteoarthritis (OA) and rheumatoid arthritis (RA) patients." | 5.12 | Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen. ( Lefkowith, JL; Verburg, KM; West, CR; Whelton, A, 2006) |
| "We performed a placebo-controlled, randomized study to address whether celecoxib or ibuprofen undermines the functional range of inhibition of platelet cyclooxygenase (COX)-1 activity by aspirin in patients with osteoarthritis and stable ischemic heart disease." | 5.12 | Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. ( Capone, ML; D'Amelio, E; De Caterina, R; Grana, M; Patrignani, P; Patrono, C; Price, TS; Renda, G; Sacchetta, D; Santarelli, F; Sciulli, MG; Tacconelli, S; Zimarino, M; Zurro, M, 2006) |
| "To determine the cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib." | 5.12 | Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib. ( Abramson, SB; Chesebro, JH; Farkouh, ME; Fuster, V; Greenberg, JD; Hochman, JS; Jeger, RV; Kirshner, H; Lay, CL; Matchaba, PT; Mellein, B; Ramanathan, K; Ruland, S; Verheugt, FW, 2007) |
| "Patients with osteoarthritis (age, >or=50 y) were randomized to receive lumiracoxib 400 mg once daily, naproxen 500 mg twice daily, or ibuprofen 800 mg 3 times daily for 12 months." | 5.12 | Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study. ( Gitton, X; Hawkey, CJ; Krammer, G; Matchaba, P; Mellein, B; Richard, D; Sallstig, P; Smalley, W; Stricker, K; Weinstein, WM, 2007) |
| "We compared the efficacy of etoricoxib 30 mg to placebo and ibuprofen 2400 mg for the treatment of osteoarthritis (OA) of the hip and knee." | 5.12 | A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis. ( Berrocal, A; Boice, JA; Cichanowitz, N; Fidelholtz, JL; Ko, A; Littlejohn, TW; Miranda, P; Puopolo, A; Reicin, AS, 2007) |
| "To compare efficacy of pain syndrome relief in osteoarthrosis at conventional administration and ultraphonophoresis of ibuprofen (nurofen gel), we applied ultraphonophoresis of 5% gel nurofen to affected joints of 20 patients of the study group (twice a day with a 5-6 hour interval; the third time the gel was applied locally in the evening)." | 5.12 | [Efficacy of ibuprofen (nurofen gel) ultraphonophoresis for pain relief in osteoarthrosis]. ( Serikov, NP, 2007) |
| "The Therapeutic Arthritis Research and Gastrointestinal Event Trial was a randomized, double-blind, 52-week study of lumiracoxib 400 mg once daily (two to four times the recommended dose for osteoarthritis) versus naproxen 500 mg twice daily or ibuprofen 800 mg three-times daily in patients with osteoarthritis." | 5.11 | Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics. ( Ehrsam, E; Farkouh, M; Gitton, X; Hawkey, CJ; Huels, J; Richardson, P, 2004) |
| "Osteoarthritis patients > or =50 years of age without ulcers or erosive esophagitis at baseline endoscopy were assigned randomly to placebo, enteric-coated aspirin 81 mg/day, rofecoxib 25 mg combined with aspirin 81 mg/day, or ibuprofen 800 mg 3 times a day." | 5.11 | Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. ( Laine, L; Maller, ES; Quan, H; Simon, T; Yu, C, 2004) |
| "In patients with OA, lumiracoxib 200 mg or 400 mg qd was associated with a significantly lower risk of gastroduodenal ulceration than ibuprofen 800 mg tid, and was similar to celecoxib 200 mg qd." | 5.11 | Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis. ( Cousin, M; Fiedorowicz-Fabrycy, IF; Gitton, X; Hawkey, CC; Hoexter, G; Nasonov, EL; Pikhlak, EG; Svoboda, P, 2004) |
| "We provided n-of-1 trials for osteoarthritis (OA), comparing paracetamol and ibuprofen; and attention deficit hyperactivity disorder (ADHD), comparing dexamphetamine or methylphenidate and placebo." | 5.11 | Using n-of-1 trials as a clinical tool to improve prescribing. ( Clavarino, AM; Del Mar, CB; Nikles, CJ, 2005) |
| "To directly compare the efficacy and safety of etoricoxib, 30 mg once daily, ibuprofen, 800 mg 3 times daily, and placebo for treatment of osteoarthritis (OA) of the hip and knee." | 5.11 | Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial. ( Aversano, ML; Boice, JA; Ko, A; Murphy, FT; Reicin, AS; Sheldon, EA; Wiesenhutter, CW; Wittmer, BA, 2005) |
| " This study sought to evaluate dyspepsia-related health in osteoarthritis (OA) and rheumatoid arthritis (RA) patients taking valdecoxib compared with patients taking nonspecific NSAIDs." | 5.11 | Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis. ( Goldstein, JL; Mayne, TJ; Rabeneck, L; Rublee, DA; Vu, A, 2005) |
| "Because in vitro studies have shown that nimesulide not only preferentially inhibits COX-2 but also reduces the action/release of pro-inflammatory cytokines, down-regulates the synthesis and/or activity of collagenase(s), and releases reactive oxygen species and other toxic substances from neutrophils, this study investigated whether nimesulide and ibuprofen could affect levels of biochemical markers of joint inflammation and collagen catabolism in patients with flare-up of knee or hip osteoarthritis." | 5.11 | Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis. ( Bevilacqua, M; Devogelaer, JP; Famaey, JP; Manicourt, DH; Righini, V, 2005) |
| " Overall, the data indicate that administration of valdecoxib offers similar efficacy for the treatment of osteoarthritis but improved upper-gastrointestinal safety compared with the conventional NSAIDs, ibuprofen and diclofenac, based on the significantly lower incidence of gastroduodenal ulcers detected by endoscopy." | 5.10 | Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis. ( Agrawal, NM; Kent, JD; Recker, DP; Sikes, DH; Verburg, KM; Zhao, WW, 2002) |
| " We hypothesized that COX-2-specific inhibition with rofecoxib (25 mg once daily) in the treatment of patients with osteoarthritis would cause fewer gastroduodenal ulcers than an equally effective dose of ibuprofen (800 mg 3 times a day), a nonspecific COX inhibitor." | 5.09 | A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group. ( Bath, R; Bolognese, J; Harper, S; Johanson, J; Laine, L; Quan, H; Schwartz, H; Simon, T; Stern, S, 1999) |
| "Ginger extract was compared to placebo and Ibuprofen in patients with osteoarthritis of the hip or knee in a controlled, double blind, double dummy, cross-over study with a wash-out period of one week followed by three treatment periods in a randomized sequence, each of three weeks duration." | 5.09 | A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis. ( Andersen, LA; Barslev, J; Bliddal, H; Christensen, K; Ibfelt, HH; Jensen, ON; Rosetzsky, A; Schlichting, P; Weidner, MS, 2000) |
| "Both doses of rofecoxib demonstrated efficacy clinically comparable with ibuprofen as assessed by 3 primary end points (pain walking on a flat surface [Western Ontario and McMaster Universities Osteoarthritis Index], patient global assessment of response to therapy, and investigator global assessment of disease status) according to predefined comparability criteria." | 5.09 | A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group. ( Bolognese, J; Castaneda, O; Daniels, B; Day, R; Ehrich, E; Helgetveit, KB; Kress, B; Krupa, D; Luza, A; Morrison, B; Nahir, M; Seidenberg, B; Strusberg, A, 2000) |
| "12-week within-patient, randomised, double-blind, placebo-controlled, crossover comparison of ibuprofen with paracetamol for osteoarthritis, involving three pairs of two-week treatment periods for each participating patient." | 5.09 | Preliminary experiences with a single-patient trials service in general practice. ( Clavarino, A; Del Mar, CB; Duggan, CM; Glasziou, PP; Nikles, CJ; Yelland, MJ, 2000) |
| "In healthy subjects, treatment with rofecoxib, at 2 to 4 times the doses that are currently recommended for the treatment of patients with osteoarthritis, produced significantly less fecal blood loss than a therapeutic dose of ibuprofen and was equivalent to placebo." | 5.09 | A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects. ( Bolognese, JA; Bowen, B; Cagliola, A; Hunt, RH; James, C; Mortensen, ER; Quan, H; Simon, TJ, 2000) |
| "The pharmacokinetic interactions between BAY 12-9566 and two nonsteroidal anti-inflammatory drugs (NSAIDs), naproxen and ibuprofen, were investigated in osteoarthritis (OA) patients." | 5.09 | Pharmacokinetics, safety, and tolerability of BAY 12-9566 and nonsteroidal anti-inflammatory agents (naproxen, ibuprofen) during coadministration in patients with osteoarthritis. ( Agarwal, V; Liu, P; Shah, A; Sundaresan, P; Woodruff, M, 2001) |
| "To compare the treatment potential of glucosamine sulfate (GS) and ibuprofen in patients diagnosed with temporomandibular joint (TMJ) osteoarthritis (OA)." | 5.09 | Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: a randomized double blind controlled 3 month clinical trial. ( Major, PW; Prasad, NG; Thie, NM, 2001) |
| "We analysed pooled data from two identical double-blind, randomized, 12-week endoscopy studies which compared the gastroduodenal toxicity of placebo (n=371), rofecoxib 25 mg (n=390), rofecoxib 50 mg (n=379), and ibuprofen 2400 mg daily (n=376) in patients with osteoarthritis." | 5.09 | Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials. ( Bolognese, JA; Harper, SE; Hawkey, CJ; Laine, L; Mortensen, E; Quan, HU, 2001) |
| "Fifteen women with arthritis and hypertension who were receiving lisinopril and HCT, and administered sequentially in random order ibuprofen, sulindac, and diclofenac for one month each, with an intervening two-week washout period between each treatment period." | 5.09 | Effects of non-steroidal anti-inflammatory drugs on hypertension control using angiotensin converting enzyme inhibitors and thiazide diuretics. ( Bhagat, K, 2001) |
| "In this randomized double-blind, parallel-group study the efficacy of 300 mg oral dexibuprofen three times daily and 50 mg oral diclofenac sodium three times daily was tested for equivalence in 110 patients with painful osteoarthritis of the knee." | 5.08 | [Double-blind comparative study of the effectiveness and tolerance of 900 mg dexibuprofen and 150 mg diclofenac sodium in patients with painful gonarthrosis]. ( Brugger, A; Hawel, R; Klein, G; Mitterhuber, J, 1997) |
| "A double-blind therapeutic investigation was performed on 178 Chinese patients suffering from osteoarthritis of the knee randomized into two groups, one treated for 4 weeks with glucosamine sulfate (GS, CAS 29031-19-4, Viartril-S) at the daily dose of 1,500 mg and the other with ibuprofen (IBU, CAS 15687-27-1) at the daily dose of 1,200 mg." | 5.08 | Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis. ( Gao, SN; Giacovelli, G; Qiu, GX; Rovati, L; Setnikar, I, 1998) |
| "The duration of action of sustained-release ibuprofen ('Brufen Retard') was investigated in a 14-day double-blind study involving 14 osteoarthritis and 10 rheumatoid arthritis patients." | 5.07 | Investigation into the duration of action of sustained-release ibuprofen in osteoarthritis and rheumatoid arthritis. ( Fernandes, L; Jenkins, R, 1994) |
| "In a randomized, open-label, controlled, multicenter, 12-week study, the efficacy and safety of nabumetone (1,000-2,000 mg/day) versus diclofenac (100-200 mg/day), naproxen (500-1,500 mg/day), ibuprofen (1,200-3,200 mg/day), or piroxicam (10-20 mg/day) were evaluated in patients with osteoarthritis (OA) or rheumatoid arthritis (RA)." | 5.07 | Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly. ( DeLapp, RE; Morgan, GJ; Poland, M, 1993) |
| "The efficacy of nabumetone was compared with that of diclofenac, naproxen, ibuprofen, and piroxicam in patients with osteoarthritis (OA) or rheumatoid arthritis (RA) in a randomized, controlled, open-label, multicenter trial." | 5.07 | Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Lister, BJ; Poland, M, 1993) |
| "The objective of this study is to utilize a clinical trial based on a decision-analysis model to assess the economic benefit of a lower incidence of gastrointestinal lesions in elderly patients with osteoarthritis receiving nabumetone therapy compared with ibuprofen alone and in combination with misoprostol." | 5.07 | A decision analysis model in the evaluation of NSAIDs in a managed care setting: a case study. ( Brixner, DI, 1994) |
| "Our randomized double blinded comparison of acetaminophen versus analgesic and antiinflammatory doses of ibuprofen in the treatment of 182 subjects with knee osteoarthritis (OA) systematically evaluated soft tissue tenderness and joint swelling." | 5.07 | Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic. ( Bradley, JD; Brandt, KD; Kalasinski, LA; Katz, BP; Ryan, SI, 1992) |
| "The pharmacokinetics of the enantiomers of ibuprofen have been investigated following oral administration of 300 or 600 mg of racemic ibuprofen four times daily to 45 patients with osteoarthritis." | 5.07 | Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients. ( Bradley, JD; Hall, SD; Kalasinski, LA; Rudy, AC; Ryan, SI; Xiaotao, Q, 1992) |
| "Stereoselective pharmacokinetic measurements of the active enantiomer, S-ibuprofen, were correlated with clinical response in 45 participants in a randomized double blinded 4 week comparison of ibuprofen, 1200 or 2400 mg/day, for treatment of hip or knee osteoarthritis." | 5.07 | Correlation of serum concentrations of ibuprofen stereoisomers with clinical response in the treatment of hip and knee osteoarthritis. ( Bradley, JD; Brandt, KD; Brater, DC; Hall, SD; Kalasinski, LA; Katz, BP; Rudy, AC; Ryan, SI, 1992) |
| "In an open three-center pilot study, 17 patients suffering from chronic persistent pain syndrome, due to osteoarthritis of the hip and knee or spondylarthrosis, were treated orally with 1800-2400 mg Ibuprofen per day for 3 weeks." | 5.07 | [Real time collection of pain profile in treatment with ibuprofen]. ( Brackertz, D; Gerbershagen, HU; Leonhart, E; Lutz, J; Panhans, C; Schröder, M; Wagenhäuser, FJ, 1991) |
| "In a randomized, double-blind trial, 184 patients with chronic knee pain due to osteoarthritis were given either 2400 or 1200 mg of ibuprofen per day or 4000 mg of acetaminophen per day." | 5.07 | Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. ( Bradley, JD; Brandt, KD; Kalasinski, LA; Katz, BP; Ryan, SI, 1991) |
| "3,672 patients with activated osteoarthritis were treated for 20 days with daily doses of 1,800 to 2,400 mg ibuprofen (Anco)." | 5.06 | ["Morning type" and "evening type" in activated osteoarthritis. Analysis and practice-related conclusions of an open, multicenter study with ibuprofen]. ( Karrasch, KF; Moerchel, J, 1989) |
| "Twenty-eight patients with osteoarthritis participated in a prospective, double-blind, cross-over study to compare the safety and efficacy of a new combination analgesic containing ibuprofen 200 mg, paracetamol 250 mg and codeine phosphate 10 mg per tablet (Myprodol; Rio Ethicals) with a standard treatment regimen (ibuprofen 200 mg per tablet)." | 5.06 | Comparison of a standard ibuprofen treatment regimen with a new ibuprofen/paracetamol/codeine combination in chronic osteo-arthritis. ( van Vuren, JP; Vlok, GJ, 1987) |
| "Despite a wide range of study designs, a multiplicity of international trials of diclofenac in osteoarthritis have disclosed similar results." | 5.06 | International experiences with diclofenac in osteoarthritis. ( Altman, R, 1986) |
| "The incidence of potentially serious drug-related elevations of BUN or serum creatinine was examined among 1468 patients with rheumatoid arthritis or osteoarthritis who took daily therapeutic doses of aspirin, ibuprofen, or oxaprozin, an investigational nonsteroidal antiinflammatory drug (NSAID), in multicenter clinical trials." | 5.06 | Renal safety of two analgesics used over the counter: ibuprofen and aspirin. ( Bonney, SL; Hedrich, DA; Northington, RS; Walker, BR, 1986) |
| "One hundred forty-one subjects with osteoarthritis completed this double-blind, multicenter, crossover trial comparing four nonsteroidal anti-inflammatory (NSAI) agents after single-blind aspirin stabilization." | 5.05 | Four-way, multicenter, crossover trial of ibuprofen, fenoprofen calcium, naproxen, and tolmetin sodium in osteoarthritis: comparative clinical profiles. ( Caldwell, JR; Crain, D; Hoffmeister, RT; Kantrowitz, F; Lloyd, RJ; Nussdorf, RT; Repice, MR; Schmid, FR, 1983) |
| "Two multi-centre studies were carried out in general practice comparing tiaprofenic acid ('Surgam') with five other non-steroidal anti-inflammatory agents (ibuprofen, indomethacin, naproxen, piroxicam and benoxaprofen), one in rheumatoid arthritis and one in osteoarthritis." | 5.05 | A multi-centre study of tiaprofenic acid ('Surgam') and five comparative drugs in rheumatoid arthritis and osteoarthritis in general practice. ( Clarke, TK; Mungavin, JM, 1983) |
| "43 patients with osteoarthritis of the knee and/or hip(s) were treated with suprofen 800 mg/day or ibuprofen 1,600 mg/day for 14 days." | 5.05 | Comparison of suprofen and ibuprofen in the treatment of pain secondary to osteoarthritis. ( Schuermans, Y, 1983) |
| "A total of 226 patients with osteoarthritis of the hip, knee or spine was entered into a general practice, multi-centre, crossover study of 500 mg naproxen twice daily and 400 mg ibuprofen 3-times daily." | 5.05 | A study of naproxen and ibuprofen in patients with osteoarthritis seen in general practice. The Manchester General Practitioner Group. ( , 1984) |
| "One hundred and thirty-one patients with osteoarthritis of the knee or hip entered a comparative trial of sustained release (SR) ibuprofen ('Fenbid') and piroxicam ('Feldene')." | 5.05 | Is sustained-release ibuprofen as effective as piroxicam? A comparison in patients with osteoarthritis. ( Cornhill, J; Rowley-Jones, D, 1984) |
| "A study was carried out in 30 elderly patients, aged between 65 and 89 years, with osteoarthritis of the hip and/or knee joints to assess the efficacy and tolerance of sulindac compared with ibuprofen." | 5.05 | A study of sulindac versus ibuprofen in elderly patients with osteoarthritis. ( Admani, AK; Verma, S, 1983) |
| "A double-blind within-patient crossover trial compared the new nonsteroidal antiinflammatory agent benoxaprofen with ibuprofen in the treatment of osteoarthritis in 31 patients." | 5.05 | Benoxaprofen in the treatment of osteoarthritis--a comparison with ibuprofen. ( Grahame, R; Highton, J, 1980) |
| " Gastrointestinal side effects with benoxaprofen compared favorably to those reported during aspirin and ibuprofen therapy, with peptic ulcers reported in 0." | 5.05 | Long-term safety of benoxaprofen. ( Mikulaschek, WM, 1980) |
| "A total of 120 general practice patients with osteoarthritis of the knee or hip received either benoxaprofen 600 mg mane or ibuprofen 400 mg tid for 4 months in a double-blind, parallel trial." | 5.05 | A comparative study of benoxaprofen and ibuprofen in osteoarthritis in general practice. ( Glynne, A; Tyson, VC, 1980) |
| "Benoxaprofen was compared to aspirin or to ibuprofen in 2 28-wk multiclinic double-blind trials in patients with symptomatic osteoarthritis of the knees or hips." | 5.05 | Long-term treatment of symptomatic osteoarthritis with benoxaprofen. Double-blind comparison with aspirin and ibuprofen. ( Alarcon-Segovia, D, 1980) |
| "A double-blind crossover study compared sodium meclofenamate (300 mg daily) and ibuprofen (900 mg daily) in thirty patients with osteoarthritis." | 5.05 | Short-term treatment of osteoarthritis: a comparison of sodium meclofenamate and ibuprofen. ( Accardo, S; Cimmino, MA; Cutolo, M; Samantà, E, 1982) |
| "Thirty-two elderly patients with symptomatic osteoarthritis predominantly of the hip and/or knee joints were randomly treated on an open basis for 12 weeks with either 400 mg sulindac or 1200 mg ibuprofen per day." | 5.05 | A randomized comparison between sulindac and ibuprofen in osteoarthritis of the aged. ( Ghosh, AK; Rastogi, AK, 1981) |
| "A randomized double-blind multicentre clinical trial was carried out to verify the effectiveness and tolerance of S-adenosylmethionine (SAMe) versus ibuprofen in 150 patients with hip and/or knee osteoarthritis." | 5.05 | Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis. ( Cherie-Ligniere, G; Colombo, B; Giordano, M; Glorioso, S; Leardini, G; Marcolongo, R; Mattara, L; Mazzi, A; Passeri, M; Todesco, S, 1985) |
| "In a double-blind, multiclinic study, 437 patients with osteoarthritis were treated sequentially with ibuprofen, 1,800 mg/day, and placebo, or with aspirin, 3,600 mg/day, and placebo." | 5.04 | Ibuprofen in osteoarthritis. ( Brooks, CD; Donaldson, MS; Giansiracusa, JE; Koonce, ML; Lefton, TE; Ruoff, GE, 1977) |
| "A randomized double-blind study in ambulatory patients with osteoarthritis of hip and/or knee was conducted, comparing the efficacy and safety of diflunisal 500 mg daily with ibuprofen 1200 mg daily, and a period of 8 weeks." | 5.04 | A comparative clinical trial of diflunisal and ibuprofen in the control of pain in osteoarthritis. ( Keet, JG, 1979) |
| "Flurbiprofen and ibuprofen, two propionic acid derivatives with anti-inflammatory and analgesic activity, were compared in a double-blind multiclinic study in 195 patients with osteoarthritis of the peripheral joints." | 5.04 | Response of osteoarthritis to ibuprofen or flurbiprofen. ( Ehrlich, GE; Giansiracusa, J; Gray, J; Mena, HR; Ward, J, 1976) |
| "Eye evaluations before and after 24 weeks of treatment with either ibuprofen (Motrin) or aspirin did not show eye toxicity with either drug in a double-blind study of 78 patients with osteoarthritis." | 5.04 | Ibuprofen and visual function. Prospective evaluation. ( Brooks, CD; Cross, CJ; Melluish, JW; Ruoff, G; Sanborn, EC, 1975) |
| "In a double-blind multiclinic trial, a new nonsteroidal anti-inflammatory agent (ibuprofen) was compared with an established therapeutic agent (phenylbutazone-alka) for the treatment of osteoarthritis." | 5.04 | Ibuprofen versus buffered phenylbutazone in the treatment of osteoarthritis: double-blind trial. ( Donovan, JF; Hearron, MS; Levi, L; Moxley, TE; Royer, GL, 1975) |
| "Oxaceprol, a derivative of l-proline, is an established drug for managing osteoarthritis (OA) with better safety profile than non-steroidal anti-inflammatory drugs (NSAIDs)." | 5.01 | A systematic review and meta-analysis of oxaceprol in the management of osteoarthritis: An evidence from randomized parallel-group controlled trials. ( Bhate, J; Durg, S; Lobo, M; Rao, G; Venkatachalam, L, 2019) |
| "Although anti-inflammatory doses of ibuprofen are very effective in treating the signs and symptoms of osteoarthritis (OA), they come with an increased risk for gastrointestinal damage which can limit their use and decrease patient adherence to therapy." | 4.90 | Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials. ( Bello, AE; Grahn, AY; Holt, RJ; Kent, JD; Rice, P, 2014) |
| "The aim of this meta-analysis based on the literature was to gather all evidence of randomized clinical trials to assess the efficacy of adenosylmethionine (SAM) and oxaceprol in the treatment of osteoarthritis." | 4.81 | [Meta-analysis of the efficacy of adenosylmethionine and oxaceprol in the treatment of osteoarthritis]. ( Lasek, R; Victor, N; Witte, S, 2002) |
| "To determine the effectiveness of oral glucosamine with ibuprofen for the relief of joint pain in osteoarthritis a mini-review (Griffiths, 2002) of double-blind randomized controlled trials comparing the two was undertaken." | 4.81 | Glucosamine therapy compared to ibuprofen for joint pain. ( Griffiths, P; Ruane, R, 2002) |
| "Prespecified analysis of all 8 double-blind, randomized phase 2b/3 rofecoxib osteoarthritis trials conducted from December 1996 through March 1998, including one 6-week dose-ranging study, two 6-week efficacy studies vs ibuprofen and placebo, two 1-year efficacy studies vs diclofenac, two 6-month endoscopy studies vs ibuprofen and placebo, and one 6-week efficacy study vs nabumetone and placebo." | 4.80 | Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. ( Bolognese, JA; Harper, SE; Jensen, DM; Langman, MJ; Quan, H; Simon, TJ; Watson, DJ; Zhao, PL, 1999) |
| "Celecoxib is the first COX-2-specific inhibitor approved for relief of the signs and symptoms of osteoarthritis (OA) and rheumatoid arthritis (RA), as well as for treatment of familial adenomatous polyposis." | 4.80 | Celecoxib clinical profile. ( Tive, L, 2000) |
| " Published data indicate that diclofenac 75 to 150mg daily (25 to 50mg 3 times daily) is comparable in efficacy with ordinary aspirin 3 to 5g daily and indomethacin 75 to 150mg daily in rheumatoid arthritis and with indomethacin in osteoarthritis." | 4.76 | Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin. ( Avery, GS; Brogden, RN; Heel, RC; Pakes, GE; Speight, TM, 1980) |
| "Nonsteroidal antiinf lammatory drugs (NSAIDs) remain the mainstay of the pharmacologic management for relieving osteoarthritis pain, and low-dose aspirin is often prescribed to osteoarthritis patients who are at high risk of cardiovascular disease (CVD)." | 4.31 | Interactions of Nonsteroidal Antiinflammatory Drugs and Aspirin and Risk of Cardiovascular Disease in Patients With Osteoarthritis. ( Lane, NE; Lei, G; Li, X; Wei, J; Zeng, C; Zhang, Y, 2023) |
| "Ibuprofen is a classical nonsteroidal anti-inflammatory drug (NSAID) highly prescribed to reduce acute pain and inflammation under an array of conditions, including rheumatoid arthritis, osteoarthritis, dysmenorrhea, and gout." | 4.02 | Ibuprofen-based advanced therapeutics: breaking the inflammatory link in cancer, neurodegeneration, and diseases. ( Amanullah, A; Dhiman, R; Joshi, V; Mishra, A; Poluri, KM; Prajapati, VK; Upadhyay, A, 2021) |
| "We identified randomised controlled trials (RCTs) of diclofenac with planned study duration of at least 4 weeks for the treatment of osteoarthritis (OA) from 'legacy' studies conducted by Novartis but not published in a peer reviewed journal or included in any previous pooled analyses." | 3.85 | Efficacy and safety of diclofenac in osteoarthritis: Results of a network meta-analysis of unpublished legacy studies. ( Andrew Moore, R; Chaves, RL; Guyot, P; Iqbal, A; Nixon, RM; Pandhi, S, 2017) |
| "The objectives of this study were (1) to fabricate ibuprofen-loaded porous microspheres (IBU/PMSs), (2) to evaluate the in vitro anti-inflammatory effects of the microspheres using LPS-induced inflammation in cultured synoviocytes, and (3) to evaluate the in vivo effect of the IBU/PMSs on the progression of monosodium iodoacetate (MIA)-induced osteoarthritis (OA) in a rat model." | 3.83 | Ibuprofen-loaded porous microspheres suppressed the progression of monosodium iodoacetate-induced osteoarthritis in a rat model. ( Kim, HJ; Kim, SE; Lee, JY; Park, JW; Park, K; Song, HR; Yun, YP, 2016) |
| "Single-tablet ibuprofen/famotidine is approved by the US Food and Drug Administration for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal (GI) ulcers in patients taking ibuprofen for those indications." | 3.79 | Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis. ( Holt, RJ; Johnson, KE; Kent, JD; Kuan, R; Malone, D; Peura, DA, 2013) |
| "The effects of long-term use of celecoxib, ibuprofen, and indomethacin on types I, II, and III collagen metabolism were evaluated in rat osteoarthritis (OA) model." | 3.78 | The effects of NSAIDs on types I, II, and III collagen metabolism in a rat osteoarthritis model. ( An, H; Jiang, DM; Luo, XJ; Ou, YS; Quan, ZX; Tan, C; Tang, K, 2012) |
| "The FDA has approved Duexis (Horizon), a fixed-dose combination of the nonsteroidal anti-inflammatory drug (NSAID) ibuprofen and the H2-receptor antagonist (H2RA) famotidine, for symptomatic relief of osteoarthritis and rheumatoid arthritis and to decrease the risk of developing gastric and duodenal ulcers in patients at risk for NSAID-associated ulcers." | 3.77 | A fixed-dose combination ibuprofen and famotidine (Duexis). ( , 2011) |
| "A case of periorbital edema associated with separate courses of ibuprofen and naproxen is reported." | 3.76 | Periorbital edema associated with separate courses of ibuprofen and naproxen. ( Balas, M; Plakogiannis, R; Sinnett, M, 2010) |
| "A 76-year-old white man with normal mental status became confused, was lost in familiar places, and showed short-term memory loss after beginning a therapeutic regimen of ibuprofen 600 mg 3 times daily for osteoarthritis in anticipation of embarking on a foreign trip." | 3.72 | Pseudodementia associated with use of ibuprofen. ( Bernstein, AL; Werlin, A, 2003) |
| "A total of 3639 patients with rheumatoid arthritis (RA), osteoarthritis, and fibromyalgia starting therapy of celecoxib, rofecoxib, naproxen, or ibuprofen were surveyed at 6-month intervals for up to 2." | 3.72 | Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice. ( Burke, TA; Michaud, K; Wolfe, F; Zhao, SZ, 2004) |
| " To compare the risk for thrombotic cardiovascular events among patients receiving rofecoxib, nonselective NSAIDs, and placebo, cardiovascular safety was assessed in 5,435 participants in 8 phase IIB/III osteoarthritis trials." | 3.71 | Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone). ( Barr, E; Reicin, AS; Shapiro, D; Sperling, RS; Yu, Q, 2002) |
| "This study combined existing data to test the hypothesis that GI comedications and GI diagnostic procedures occur less frequently in osteoarthritis (OA) patients treated with rofecoxib compared with nonselective NSAIDs." | 3.71 | Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs. ( Bolognese, JA; Harper, SE; Simon, TJ; Watson, DJ; Zhao, PL, 2001) |
| "The incidence of lower extremity edema (LEE) AEs was generally similar between rofecoxib 12." | 3.71 | A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. ( Bolognese, JA; Gertz, BJ; Krupa, D; Reicin, A; Sperling, RS, 2002) |
| "To investigate recent national trends in nonsteroidal antiinflammatory drug (NSAID) and acetaminophen use for osteoarthritis (OA)." | 3.71 | Trends in medication use for osteoarthritis treatment. ( Ausiello, JC; Stafford, RS, 2002) |
| "To analyze results of treatment of osteoarthritis (OA) with acetaminophen and the nonsteroidal antiinflammatory drugs (NSAID) through a patient survey." | 3.70 | Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis. ( Callahan, LF; Cummins, P; Pincus, T; Swearingen, C, 2000) |
| " We compared the 3-month direct medical costs, including those associated with treating NSAID-induced adverse events, of nabumetone, ibuprofen, or ibuprofen plus misoprostol in 171 elderly patients with osteoarthritis." | 3.69 | Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol. ( Baker, AM; Bentkover, JD; Kaplan, H, 1994) |
| "An open design has been carried out by the authors comparing the efficacy and the tolerance of galactosoaminoglucuronoglycan sulfates (GAGs) with those of ibuprofen lysine in patients affected by osteoarthritis (OA)." | 3.68 | Clinical efficacy and tolerance of galactosoaminoglucuronoglycan sulfate in the treatment of osteoarthritis. ( Anselmi, F; Fattorini, L; Fioravanti, A; Franci, A; Marcolongo, R, 1991) |
| "A patient taking ibuprofen (Motrin) for the relief of osteoarthritis developed, after two months, decreased visual acuity and decreased color vision." | 3.67 | Visual evoked potentials and ibuprofen (Motrin) toxicity. ( Beckman, H; Hamburger, HA; Thompson, R, 1984) |
| "Studies with benoxaprofen in rheumatoid arthritis and osteoarthritis, conducted in more than 2000 patients, continue to demonstrate its safety and effectiveness." | 3.66 | An update on long-term efficacy and safety with benoxaprofen. ( Mikulaschek, WM, 1982) |
| "Thirty-two elderly patients with symptomatic osteoarthritis, mainly of the hip and/or knee joints, were treated at random with either 400 mg sulindac or 1200 mg ibuprofen per day for 12 weeks." | 3.66 | Symptomatic osteoarthritis in the elderly: a comparative study of sulindac and ibuprofen. ( Ghosh, AK; Rastogi, AK, 1982) |
| "An open, multi-centre study was carried out in 239 elderly out-patients referred with symptomatic osteoarthritis of the hip and/or knee to assess the effectiveness of 200 mg sulindac twice daily compared with either 400 mg ibuprofen 3-times daily, 250 mg naproxen twice daily or 25 mg diclofenac 3-times daily." | 3.66 | Osteoarthritis and non-steroidal and anti-inflammatory drugs: a multi-centre comparative study. ( Pathy, MS, 1982) |
| " Phenylbutazone (Butazolidin) is probably the drug of choice for acute gout and is also effective in ankylosing spondylitis, Reiter's syndrome, and psoriatic arthritis." | 3.65 | Rheumatic diseases. 2. Therapeutic considerations. ( Biundo, JJ; Gum, OB; Weiss, TE, 1976) |
| "Ibuprofen is a new, mild analgesic agent that may be useful in the symptomatic treatment of rheumatoid arthritis and osteoarthritis." | 3.65 | Evaluation of ibuprofen (Motrin). A new antirheumatic agent. ( Lewis, JR, 1975) |
| "Ibuprofen generally was found to be toxic, mutagenic, teratogenic and genotoxic agent in various organisms." | 3.01 | Toxic, Genotoxic and Teratogenic Effects of Ibuprofen and its Derivatives. ( Çalışıcı, D; Goktas, B; Yılmaz, S, 2023) |
| " The risk score was designed to predict the 1-year occurrence of major toxicity among NSAID users, including major adverse cardiovascular events, acute kidney injury, significant gastrointestinal events, and mortality." | 2.90 | Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial. ( Husni, ME; Nissen, S; Paynter, N; Shao, M; Solomon, DH; Wolski, K, 2019) |
| " The outcome was major nonsteroidal anti-inflammatory drug toxicity, including time to first occurrence of major adverse cardiovascular events, important gastrointestinal events, renal events, and all-cause mortality." | 2.84 | The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial. ( Borer, JS; Brennan, DM; Husni, ME; Libby, PA; Lincoff, AM; Lϋscher, TF; Menon, V; Nissen, SE; Solomon, DH; Wisniewski, LM; Yeomans, ND, 2017) |
| " Future clinical trials should investigate this association with maximum dosage of drugs, increased treatment duration, and monitoring of social and environmental changes." | 2.78 | NSAIDs are associated with lower depression scores in patients with osteoarthritis. ( Aneja, A; Farkouh, ME; Gandhi, S; Greenberg, J; Iyengar, RL; Mosovich, S; Razzouk, L; Thorpe, K, 2013) |
| "Ibuprofen-PC is an effective osteoarthritic agent with an improved GI safety profile compared with ibuprofen in older OA patients, who are most susceptible to NSAID-induced gastroduodenal injury." | 2.73 | Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients. ( Anand, BS; Lanza, FL; Lichtenberger, LM; Marathi, UK, 2008) |
| "100 patients with femorotibial gonarthrosis aged 45 years and older entered an open randomised trial." | 2.69 | [Structum (chondroitin sulfate)--a new agent for the treatment of osteoarthrosis]. ( Alekseeva, LI; Benevolenskaia, LI; Chichasova, NV; Kariakin, AN; Nasonov, EL, 1999) |
| "Conventional nonsteroidal anti-inflammatory drugs (NSAIDs) are associated with a spectrum of toxic effects, notably gastrointestinal (GI) effects, because of inhibition of cyclooxygenase (COX)-1." | 2.69 | Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. ( Agrawal, NM; Burr, AM; Eisen, G; Faich, G; Geis, GS; Goldstein, JL; Kent, JD; Lefkowith, JB; Makuch, R; Pincus, T; Silverstein, FE; Simon, LS; Stenson, WF; Verburg, KM; Whelton, A; Zhao, WW, 2000) |
| "Ibuprofen was also better tolerated than diclofenac sodium (100 mg/day), the latter being associated with gastrointestinal side effects in a significant proportion of patients." | 2.68 | Ibuprofen and diclofenac sodium in the treatment of osteoarthritis: a comparative trial of two once-daily sustained-release NSAID formulations. ( Baumgartner, H; Blum, W; Bruhin, A; Gallachi, G; Goldinger, G; Saxer, M; Schwarz, HA; Trost, H, 1996) |
| "Naproxen-treated patients experienced significantly (p < 0." | 2.67 | Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. ( DeLapp, RE; Eversmeyer, W; Jensen, CP; Poland, M, 1993) |
| " Finally, the worldwide database of more than 77,000 patients monitored in postmarketing surveillance studies is examined to assess gastrointestinal side effects and the relation of age and sex to these adverse events." | 2.66 | Clinical benefits and comparative safety of piroxicam. Analysis of worldwide clinical trials data. ( Meisel, AD, 1986) |
| " Adverse experiences were infrequent and generally mild or transient." | 2.66 | Worldwide clinical safety experience with diclofenac. ( Willkens, RF, 1985) |
| "Ibuprofen was significantly better than placebo for relief of morning stiffness and for reducing the amount of supplementary analgesics." | 2.64 | Butacote and ibuprofen: a comparative assessment in rheumatic diseases in general practice. ( Regalado, RG, 1977) |
| "The results indicate that in the treatment of osteoarthrosis, floctafenine is comparable to ibuprofen (in the dose used in the study) in terms of efficacy and toxicity." | 2.64 | A comparative study of floctafenine (Idarac) and ibuprofen in the treatment of osteoarthrosis. ( Akbar, FA; Downie, WW; Leatham, PA; Rhind, VM; Wright, V, 1978) |
| "Carprofen is a propionic acid-derived NSAID that has anti-inflammatory, analgesic, and antipyretic activity." | 2.40 | Use of carprofen for the treatment of pain and inflammation in dogs. ( Fox, SM; Johnston, SA, 1997) |
| "Chronic pain affects 75 million US citizens." | 2.40 | Non-NSAID pharmacologic treatment options for the management of chronic pain. ( Schnitzer, TJ, 1998) |
| "We can use from escin for the treatment of osteoarthritis as an anti-inflammatory agent in the latter but further studies to support the results from such a model are needed." | 1.48 | Evaluation of the effect of polyphenol of escin compared with ibuprofen and dexamethasone in synoviocyte model for osteoarthritis: an in vitro study. ( Hallajzadeh, J; Maghsoudi, H; Rezaeipour, M, 2018) |
| "Celecoxib has a positive effect on human osteoarthritic cartilage, but the mechanisms remain unclear." | 1.38 | Selective COX-2 inhibitor ameliorates osteoarthritis by repressing apoptosis of chondrocyte. ( An, H; Jiang, D; Luo, X; Ou, Y; Quan, Z; Tan, C; Tang, K, 2012) |
| " Given the low rates of events, at low or intermittent dosage without concurrent treatment, these 3 analgesics cannot be distinguished from each other or from background rates of serious GI toxicity." | 1.32 | Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis. ( Bruce, B; Fries, JF, 2003) |
| "The patient discussed developed severe acute renal failure after strenuous exercise and therapeutic doses of ibuprofen and hydrochlorothiazide-triamterene." | 1.29 | Exercise-induced acute renal failure associated with ibuprofen, hydrochlorothiazide, and triamterene. ( Sanders, LR, 1995) |
| " Since at the same time the tolerability of ibuprofen was also found to be good--4% side effects--it can be recommended also for long-term use in this indication." | 1.28 | [Ibuprofen--successful in activated arthrosis. Results of a administration study]. ( Hilken, K; Lewandowski, C; Rollinger, Y; Seifert, F; Vögtle-Junkert, U, 1992) |
| "Ibuprofen is a frequently used medication, and possible drug reactions should be familiar to the clinician." | 1.27 | Multiple oral petechiae and ecchymoses in a patient with osteoarthritis. ( Bellome, J; DeBoom, GW; Hiatt, WR; Schelkun, PM, 1987) |
| "A patient who developed an autoimmune hemolytic anemia during treatment with ibuprofen (Motrin) is described." | 1.26 | Coombs'-positive hemolytic anemia and ibuprofen. ( Harrison, BR; Law, IP; Wickman, CJ, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 85 (38.81) | 18.7374 |
| 1990's | 40 (18.26) | 18.2507 |
| 2000's | 54 (24.66) | 29.6817 |
| 2010's | 32 (14.61) | 24.3611 |
| 2020's | 8 (3.65) | 2.80 |
| Authors | Studies |
|---|---|
| Pemmari, A | 1 |
| Tuure, L | 1 |
| Hämäläinen, M | 1 |
| Leppänen, T | 1 |
| Moilanen, T | 1 |
| Moilanen, E | 1 |
| Yang, H | 1 |
| Hu, Y | 1 |
| Kang, M | 1 |
| Ding, H | 1 |
| Gong, Y | 1 |
| Yin, X | 1 |
| Sun, R | 1 |
| Qin, Y | 1 |
| Wei, Y | 1 |
| Huang, D | 1 |
| Çalışıcı, D | 1 |
| Yılmaz, S | 1 |
| Goktas, B | 1 |
| Xie, J | 1 |
| Brash, JT | 1 |
| Turkmen, C | 1 |
| Driessen, S | 1 |
| Varrassi, G | 1 |
| Argyriou, G | 1 |
| Seager, S | 1 |
| Reich, C | 1 |
| Prieto-Alhambra, D | 1 |
| Wei, J | 1 |
| Zeng, C | 1 |
| Lane, NE | 1 |
| Li, X | 1 |
| Lei, G | 1 |
| Zhang, Y | 2 |
| Elmazoglu, Z | 1 |
| Bek, ZA | 1 |
| Sarıbaş, GS | 1 |
| Özoğul, C | 1 |
| Goker, B | 1 |
| Bitik, B | 1 |
| Aktekin, CN | 1 |
| Karasu, Ç | 1 |
| Limami, Y | 1 |
| Leger, DY | 1 |
| Liagre, B | 1 |
| Pécout, N | 1 |
| Viana, M | 1 |
| Upadhyay, A | 1 |
| Amanullah, A | 1 |
| Joshi, V | 1 |
| Dhiman, R | 1 |
| Prajapati, VK | 1 |
| Poluri, KM | 1 |
| Mishra, A | 1 |
| Raschle, J | 1 |
| Solomon, DH | 5 |
| Husni, ME | 5 |
| Libby, PA | 1 |
| Yeomans, ND | 4 |
| Lincoff, AM | 4 |
| Lϋscher, TF | 1 |
| Menon, V | 3 |
| Brennan, DM | 1 |
| Wisniewski, LM | 4 |
| Nissen, SE | 4 |
| Borer, JS | 4 |
| Breivik, H | 1 |
| Guyot, P | 1 |
| Pandhi, S | 1 |
| Nixon, RM | 1 |
| Iqbal, A | 1 |
| Chaves, RL | 1 |
| Andrew Moore, R | 1 |
| Ruschitzka, F | 1 |
| Krum, H | 1 |
| Flammer, AJ | 1 |
| Libby, P | 3 |
| Lüscher, TF | 3 |
| Graham, DY | 3 |
| Davey, DA | 1 |
| Fayyad, R | 1 |
| Beckerman, B | 1 |
| Iorga, D | 1 |
| Adler, N | 1 |
| Schoeniger, A | 1 |
| Fuhrmann, H | 1 |
| Wolski, KE | 2 |
| Wang, Q | 2 |
| Bao, W | 2 |
| Berger, MF | 1 |
| Maghsoudi, H | 1 |
| Hallajzadeh, J | 1 |
| Rezaeipour, M | 1 |
| Stevens, T | 1 |
| Vargo, J | 1 |
| Walker, C | 1 |
| Brignardello-Petersen, R | 1 |
| Micheli, L | 1 |
| Ghelardini, C | 1 |
| Lucarini, E | 1 |
| Parisio, C | 1 |
| Trallori, E | 1 |
| Cinci, L | 1 |
| Di Cesare Mannelli, L | 1 |
| Shao, M | 1 |
| Wolski, K | 1 |
| Nissen, S | 1 |
| Paynter, N | 1 |
| Durg, S | 1 |
| Lobo, M | 1 |
| Venkatachalam, L | 1 |
| Rao, G | 1 |
| Bhate, J | 1 |
| Kuan, R | 1 |
| Holt, RJ | 3 |
| Johnson, KE | 1 |
| Kent, JD | 5 |
| Peura, DA | 1 |
| Malone, D | 1 |
| Iyengar, RL | 1 |
| Gandhi, S | 1 |
| Aneja, A | 1 |
| Thorpe, K | 1 |
| Razzouk, L | 1 |
| Greenberg, J | 1 |
| Mosovich, S | 1 |
| Farkouh, ME | 2 |
| Bello, AE | 2 |
| Grahn, AY | 1 |
| Rice, P | 1 |
| Park, JW | 1 |
| Yun, YP | 1 |
| Park, K | 1 |
| Lee, JY | 1 |
| Kim, HJ | 1 |
| Kim, SE | 1 |
| Song, HR | 1 |
| Sun, F | 1 |
| Li, Q | 1 |
| Nurmohamed, MT | 1 |
| Lanza, FL | 1 |
| Marathi, UK | 1 |
| Anand, BS | 1 |
| Lichtenberger, LM | 1 |
| MacDonald, TM | 2 |
| Reginster, JY | 1 |
| Littlejohn, TW | 2 |
| Richard, D | 3 |
| Lheritier, K | 2 |
| Krammer, G | 3 |
| Rebuli, R | 1 |
| Pavlicević, I | 1 |
| Kuzmanić, M | 1 |
| Rumboldt, M | 1 |
| Rumboldt, Z | 1 |
| Renda, G | 2 |
| Zurro, M | 2 |
| Romano, M | 1 |
| De Caterina, R | 2 |
| Caunedo-Alvarez, A | 1 |
| Gómez-Rodríguez, BJ | 1 |
| Romero-Vázquez, J | 1 |
| Argüelles-Arias, F | 1 |
| Romero-Castro, R | 1 |
| García-Montes, JM | 1 |
| Pellicer-Bautista, FJ | 1 |
| Herrerías-Gutiérrez, JM | 1 |
| Balas, M | 1 |
| Plakogiannis, R | 1 |
| Sinnett, M | 1 |
| Marini, I | 2 |
| Gatto, MR | 2 |
| Bonetti, GA | 2 |
| Ou, YS | 1 |
| Tan, C | 2 |
| An, H | 2 |
| Jiang, DM | 1 |
| Quan, ZX | 1 |
| Tang, K | 2 |
| Luo, XJ | 1 |
| Burnett, BP | 1 |
| Bitto, A | 1 |
| Altavilla, D | 1 |
| Squadrito, F | 1 |
| Levy, RM | 1 |
| Pillai, L | 1 |
| Schiff, M | 1 |
| Peura, D | 1 |
| de Souza, RF | 1 |
| Lovato da Silva, CH | 1 |
| Nasser, M | 1 |
| Fedorowicz, Z | 1 |
| Al-Muharraqi, MA | 1 |
| Bartolucci, ML | 1 |
| Bortolotti, F | 1 |
| Ou, Y | 1 |
| Jiang, D | 1 |
| Quan, Z | 1 |
| Luo, X | 1 |
| Sikes, DH | 1 |
| Agrawal, NM | 2 |
| Zhao, WW | 2 |
| Recker, DP | 1 |
| Verburg, KM | 3 |
| Witte, S | 1 |
| Lasek, R | 1 |
| Victor, N | 1 |
| Bernstein, AL | 1 |
| Werlin, A | 1 |
| Hunt, RH | 2 |
| Harper, S | 2 |
| Callegari, P | 1 |
| Yu, C | 2 |
| Quan, H | 5 |
| Evans, J | 1 |
| James, C | 2 |
| Bowen, B | 2 |
| Rashid, F | 1 |
| Brandt, KD | 4 |
| Fries, JF | 1 |
| Bruce, B | 1 |
| Shi, W | 1 |
| Wang, YM | 1 |
| Cheng, NN | 1 |
| Chen, BY | 1 |
| Li, D | 1 |
| Nowlan, C | 1 |
| Wetmore, S | 1 |
| Al Aboud, K | 1 |
| Ramesh, V | 1 |
| Al Hawsawi, K | 1 |
| Wolfe, F | 1 |
| Michaud, K | 1 |
| Burke, TA | 1 |
| Zhao, SZ | 1 |
| Idänpään-Heikkilä, JE | 1 |
| Idänpään-Heikkilä, JJ | 1 |
| Klaukka, T | 1 |
| Hawkey, CJ | 3 |
| Farkouh, M | 1 |
| Gitton, X | 3 |
| Ehrsam, E | 1 |
| Huels, J | 1 |
| Richardson, P | 1 |
| Laine, L | 3 |
| Maller, ES | 1 |
| Simon, T | 2 |
| Hawkey, CC | 1 |
| Svoboda, P | 1 |
| Fiedorowicz-Fabrycy, IF | 1 |
| Nasonov, EL | 3 |
| Pikhlak, EG | 1 |
| Cousin, M | 1 |
| Hoexter, G | 1 |
| Summerton, N | 1 |
| Oberoi, LM | 1 |
| Alexander, KS | 1 |
| Riga, AT | 1 |
| Nikles, CJ | 2 |
| Clavarino, AM | 1 |
| Del Mar, CB | 2 |
| Wiesenhutter, CW | 1 |
| Boice, JA | 2 |
| Ko, A | 2 |
| Sheldon, EA | 1 |
| Murphy, FT | 1 |
| Wittmer, BA | 1 |
| Aversano, ML | 1 |
| Reicin, AS | 3 |
| Rabeneck, L | 1 |
| Goldstein, JL | 2 |
| Vu, A | 1 |
| Mayne, TJ | 1 |
| Rublee, DA | 1 |
| Manicourt, DH | 1 |
| Bevilacqua, M | 1 |
| Righini, V | 1 |
| Famaey, JP | 1 |
| Devogelaer, JP | 1 |
| Gupta, S | 1 |
| McQuaid, K | 1 |
| Rodnick, JE | 1 |
| Luyten, FP | 1 |
| Geusens, P | 1 |
| Malaise, M | 1 |
| De Clerck, L | 1 |
| Westhovens, R | 1 |
| Raeman, F | 1 |
| Vander Mijnsbrugge, D | 1 |
| Mathy, L | 1 |
| Hauzeur, JP | 1 |
| De Keyser, F | 1 |
| Van den Bosch, F | 1 |
| Whelton, A | 2 |
| Lefkowith, JL | 1 |
| West, CR | 1 |
| Tacconelli, S | 1 |
| Capone, ML | 1 |
| Sacchetta, D | 1 |
| Santarelli, F | 1 |
| Sciulli, MG | 1 |
| Zimarino, M | 1 |
| Grana, M | 1 |
| D'Amelio, E | 1 |
| Price, TS | 1 |
| Patrono, C | 1 |
| Patrignani, P | 1 |
| Widrig, R | 1 |
| Suter, A | 1 |
| Saller, R | 1 |
| Melzer, J | 1 |
| Greenberg, JD | 1 |
| Jeger, RV | 1 |
| Ramanathan, K | 1 |
| Verheugt, FW | 1 |
| Chesebro, JH | 1 |
| Kirshner, H | 1 |
| Hochman, JS | 1 |
| Lay, CL | 1 |
| Ruland, S | 1 |
| Mellein, B | 2 |
| Matchaba, PT | 1 |
| Fuster, V | 1 |
| Abramson, SB | 1 |
| Weinstein, WM | 1 |
| Smalley, W | 1 |
| Sallstig, P | 1 |
| Stricker, K | 1 |
| Matchaba, P | 1 |
| Puopolo, A | 1 |
| Fidelholtz, JL | 1 |
| Miranda, P | 1 |
| Berrocal, A | 1 |
| Cichanowitz, N | 1 |
| Serikov, NP | 1 |
| Singh, H | 1 |
| Pipino, F | 1 |
| Busetto, M | 1 |
| Franchin, F | 1 |
| Punzi, L | 1 |
| Todesco, S | 2 |
| Caldwell, JR | 2 |
| Crain, D | 1 |
| Hoffmeister, RT | 1 |
| Kantrowitz, F | 1 |
| Lloyd, RJ | 1 |
| Nussdorf, RT | 1 |
| Schmid, FR | 1 |
| Repice, MR | 1 |
| Mungavin, JM | 1 |
| Clarke, TK | 1 |
| Schuermans, Y | 1 |
| Gburek, Z | 1 |
| Podźorski, J | 1 |
| Kiecoń, I | 1 |
| Altman, RD | 1 |
| Cornhill, J | 1 |
| Rowley-Jones, D | 1 |
| Pavelka, K | 3 |
| Susta, A | 1 |
| Vojtísek, O | 1 |
| Malecek, J | 1 |
| Machtey, I | 1 |
| Ouaknine, L | 1 |
| Michelsson, JE | 2 |
| Hunneyball, IM | 1 |
| Hamburger, HA | 1 |
| Beckman, H | 1 |
| Thompson, R | 1 |
| Currie, WJ | 1 |
| Vandenburg, MJ | 1 |
| Janke, PG | 1 |
| Diggins, JB | 1 |
| Klein, B | 1 |
| Brogden, RN | 1 |
| Heel, RC | 1 |
| Pakes, GE | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Admani, AK | 1 |
| Verma, S | 1 |
| Munn, E | 1 |
| Lynn, KL | 1 |
| Bailey, RR | 1 |
| Bunton, RW | 1 |
| Barrett, DC | 1 |
| Palmer, DG | 1 |
| Brooks, PM | 1 |
| Hill, W | 1 |
| Geddes, R | 1 |
| Highton, J | 1 |
| Grahame, R | 2 |
| Mikulaschek, WM | 2 |
| Tyson, VC | 1 |
| Glynne, A | 1 |
| Alarcon-Segovia, D | 1 |
| Cucinotta, D | 1 |
| Mancini, M | 1 |
| Ceccato, S | 1 |
| Castino, E | 1 |
| Dieppe, P | 1 |
| Doyle, D | 1 |
| Jacoby, R | 1 |
| Crook, PR | 1 |
| Fowler, PD | 1 |
| Hothersall, TE | 1 |
| Chiswell, RJ | 1 |
| Gui, L | 1 |
| Pellacci, F | 1 |
| Ghirardini, G | 1 |
| Cimmino, MA | 1 |
| Cutolo, M | 1 |
| Samantà, E | 1 |
| Accardo, S | 1 |
| Bird, HA | 1 |
| Rhind, VM | 2 |
| Leatham, PA | 2 |
| Wright, V | 2 |
| Ghosh, AK | 2 |
| Rastogi, AK | 2 |
| Pathy, MS | 1 |
| Lopes Vaz, A | 1 |
| Sedlácková, M | 1 |
| Gatterová, J | 1 |
| Becvár, R | 1 |
| Sanders, LR | 1 |
| Nasonova, VA | 1 |
| Murav'ev, IuV | 1 |
| Lebedeva, VV | 1 |
| Tsvetkova, ES | 1 |
| Chichasova, NV | 2 |
| Badokin, VV | 1 |
| Lesniak, OM | 1 |
| Demin, AA | 1 |
| Baranova, EIa | 1 |
| Fernandes, L | 1 |
| Jenkins, R | 1 |
| Dreiser, RL | 1 |
| Gersberg, M | 1 |
| Thomas, F | 1 |
| Courcier, S | 1 |
| Fullerton, T | 1 |
| Sica, DA | 1 |
| Blum, RA | 1 |
| Roth, SH | 1 |
| Tindall, EA | 1 |
| Jain, AK | 1 |
| McMahon, FG | 1 |
| April, PA | 1 |
| Bockow, BI | 1 |
| Cohen, SB | 1 |
| Fleischmann, RM | 1 |
| Eversmeyer, W | 1 |
| Poland, M | 3 |
| DeLapp, RE | 3 |
| Jensen, CP | 1 |
| Morgan, GJ | 1 |
| Lister, BJ | 1 |
| Hamdy, RC | 1 |
| Moore, SW | 1 |
| Micklewright, M | 1 |
| Beecham, VF | 1 |
| Baumgartner, H | 1 |
| Schwarz, HA | 1 |
| Blum, W | 1 |
| Bruhin, A | 1 |
| Gallachi, G | 1 |
| Goldinger, G | 1 |
| Saxer, M | 1 |
| Trost, H | 1 |
| Save, TK | 1 |
| Parmar, DV | 1 |
| Devarajan, PV | 1 |
| Hawel, R | 1 |
| Klein, G | 1 |
| Mitterhuber, J | 1 |
| Brugger, A | 1 |
| Fox, SM | 1 |
| Johnston, SA | 1 |
| Qiu, GX | 1 |
| Gao, SN | 1 |
| Giacovelli, G | 1 |
| Rovati, L | 1 |
| Setnikar, I | 1 |
| Schnitzer, TJ | 1 |
| Ronca, F | 1 |
| Palmieri, L | 1 |
| Panicucci, P | 1 |
| Ronca, G | 1 |
| Karateev, DE | 1 |
| Brixner, DI | 1 |
| Hatoum, HT | 1 |
| Kong, SX | 1 |
| Bentkover, JD | 1 |
| Baker, AM | 1 |
| Kaplan, H | 1 |
| Alekseeva, LI | 1 |
| Benevolenskaia, LI | 1 |
| Kariakin, AN | 1 |
| Bath, R | 1 |
| Johanson, J | 1 |
| Schwartz, H | 1 |
| Stern, S | 1 |
| Bolognese, J | 2 |
| Davies, GM | 2 |
| Watson, DJ | 4 |
| Bellamy, N | 2 |
| Langman, MJ | 1 |
| Jensen, DM | 1 |
| Harper, SE | 3 |
| Zhao, PL | 2 |
| Bolognese, JA | 6 |
| Simon, TJ | 3 |
| Bliddal, H | 1 |
| Rosetzsky, A | 1 |
| Schlichting, P | 1 |
| Weidner, MS | 1 |
| Andersen, LA | 1 |
| Ibfelt, HH | 1 |
| Christensen, K | 1 |
| Jensen, ON | 1 |
| Barslev, J | 1 |
| Blondon, H | 1 |
| Pincus, T | 2 |
| Swearingen, C | 1 |
| Cummins, P | 1 |
| Callahan, LF | 1 |
| Day, R | 1 |
| Morrison, B | 1 |
| Luza, A | 1 |
| Castaneda, O | 1 |
| Strusberg, A | 1 |
| Nahir, M | 1 |
| Helgetveit, KB | 1 |
| Kress, B | 1 |
| Daniels, B | 1 |
| Krupa, D | 2 |
| Seidenberg, B | 1 |
| Ehrich, E | 1 |
| Glasziou, PP | 1 |
| Duggan, CM | 1 |
| Clavarino, A | 1 |
| Yelland, MJ | 1 |
| Mortensen, ER | 1 |
| Cagliola, A | 1 |
| Silverstein, FE | 1 |
| Faich, G | 1 |
| Simon, LS | 1 |
| Makuch, R | 1 |
| Eisen, G | 1 |
| Stenson, WF | 1 |
| Burr, AM | 1 |
| Lefkowith, JB | 1 |
| Geis, GS | 1 |
| Ehrich, EW | 1 |
| Seidenberg, BC | 1 |
| Shah, A | 1 |
| Woodruff, M | 1 |
| Agarwal, V | 1 |
| Liu, P | 1 |
| Sundaresan, P | 1 |
| Tive, L | 1 |
| Thie, NM | 1 |
| Prasad, NG | 1 |
| Major, PW | 1 |
| Quan, HU | 1 |
| Mortensen, E | 1 |
| Shapiro, D | 1 |
| Sperling, RS | 2 |
| Barr, E | 1 |
| Yu, Q | 1 |
| Ruane, R | 1 |
| Griffiths, P | 1 |
| Bhagat, K | 1 |
| Gertz, BJ | 1 |
| Reicin, A | 1 |
| Ausiello, JC | 1 |
| Stafford, RS | 1 |
| Jüni, P | 1 |
| Rutjes, AW | 1 |
| Dieppe, PA | 2 |
| Tranmer, C | 1 |
| Motta, C | 1 |
| Spadoni, R | 1 |
| Pierboni, M | 1 |
| Caporalini, S | 1 |
| Oyemade, GA | 1 |
| Onadeko, BO | 1 |
| Engbaek, J | 1 |
| Giansiracusa, JE | 1 |
| Donaldson, MS | 1 |
| Koonce, ML | 1 |
| Lefton, TE | 1 |
| Ruoff, GE | 1 |
| Brooks, CD | 2 |
| Andrew, A | 1 |
| Rodda, B | 1 |
| Verhaest, L | 1 |
| Van Winzum, C | 1 |
| Regalado, RG | 1 |
| Bain, LS | 1 |
| Lynch, MP | 1 |
| Bruce, GM | 1 |
| Brackertz, B | 1 |
| Busson, M | 1 |
| Bresnihan, B | 1 |
| Hughes, G | 1 |
| Essigman, WK | 1 |
| Rubegni, M | 1 |
| Bellini, PG | 1 |
| Ferrati, G | 1 |
| Giro, C | 1 |
| Lo Presti, R | 1 |
| Keet, JG | 1 |
| Bonomo, I | 1 |
| Law, IP | 1 |
| Wickman, CJ | 1 |
| Harrison, BR | 1 |
| Akbar, FA | 1 |
| Downie, WW | 1 |
| Hingorani, K | 1 |
| Burry, HC | 1 |
| Perera, T | 1 |
| Sack, KE | 1 |
| Rosenthal, SH | 1 |
| Mena, HR | 1 |
| Ehrlich, GE | 1 |
| Giansiracusa, J | 1 |
| Ward, J | 1 |
| Gray, J | 1 |
| Royer, GL | 2 |
| Moxley, TE | 2 |
| Hearron, MS | 2 |
| Miyara, A | 1 |
| Donovan, JF | 2 |
| Melluish, JW | 1 |
| Ruoff, G | 1 |
| Cross, CJ | 1 |
| Sanborn, EC | 1 |
| Snyder, EG | 1 |
| Weiss, TE | 1 |
| Gum, OB | 1 |
| Biundo, JJ | 1 |
| Levi, L | 1 |
| McBeath, AA | 1 |
| Lewis, JR | 1 |
| Levy, NS | 1 |
| Hanscom, T | 1 |
| Bradley, JD | 4 |
| Katz, BP | 3 |
| Kalasinski, LA | 4 |
| Ryan, SI | 4 |
| Lewandowski, C | 1 |
| Hilken, K | 1 |
| Seifert, F | 1 |
| Rollinger, Y | 1 |
| Vögtle-Junkert, U | 1 |
| Rudy, AC | 2 |
| Xiaotao, Q | 1 |
| Hall, SD | 2 |
| Brater, DC | 1 |
| Ryttig, K | 1 |
| Schlamowitz, PV | 1 |
| Warnøe, O | 1 |
| Wilstrup, F | 1 |
| Keiding, N | 1 |
| Astrup, AV | 1 |
| Haase, W | 1 |
| Fischer, M | 1 |
| Brackertz, D | 1 |
| Leonhart, E | 1 |
| Gerbershagen, HU | 1 |
| Panhans, C | 1 |
| Schröder, M | 1 |
| Wagenhäuser, FJ | 1 |
| Lutz, J | 1 |
| Adam, W | 1 |
| Fioravanti, A | 1 |
| Franci, A | 1 |
| Anselmi, F | 1 |
| Fattorini, L | 1 |
| Marcolongo, R | 2 |
| Kaik, B | 1 |
| Bauer, K | 1 |
| Bröll, H | 1 |
| Stammers, T | 1 |
| Sibbald, B | 1 |
| Freeling, P | 1 |
| Doogan, DP | 1 |
| Moerchel, J | 2 |
| Karrasch, KF | 1 |
| Somerville, K | 1 |
| Faulkner, G | 1 |
| Langman, M | 1 |
| Shand, DG | 1 |
| Epstein, C | 1 |
| Kinberg-Calhoun, J | 1 |
| Mullane, JF | 1 |
| Sanda, M | 1 |
| Barnard-Jones, K | 1 |
| Davies, RW | 1 |
| Lalla, O | 1 |
| Mann, PG | 1 |
| Welch, RB | 1 |
| Vlok, GJ | 1 |
| van Vuren, JP | 1 |
| Di Perri, T | 1 |
| Auteri, A | 1 |
| Caruso, I | 1 |
| Corvetta, A | 1 |
| Danieli, G | 1 |
| Sarzi Puttini, PC | 1 |
| Scaricabarozzi, I | 1 |
| Müller-Fassbender, H | 1 |
| Schelkun, PM | 1 |
| Bellome, J | 1 |
| Hiatt, WR | 1 |
| DeBoom, GW | 1 |
| Svarcová, J | 1 |
| Trnavský, K | 1 |
| Zvárová, J | 1 |
| Altman, R | 1 |
| Bonney, SL | 1 |
| Northington, RS | 1 |
| Hedrich, DA | 1 |
| Walker, BR | 1 |
| Meisel, AD | 1 |
| Sandyk, R | 1 |
| Awerbuch, G | 1 |
| Rapcsak, SZ | 1 |
| Glorioso, S | 1 |
| Mazzi, A | 1 |
| Giordano, M | 1 |
| Colombo, B | 1 |
| Cherie-Ligniere, G | 1 |
| Mattara, L | 1 |
| Leardini, G | 1 |
| Passeri, M | 1 |
| Lambert, JR | 1 |
| Cardoe, N | 1 |
| Simpson, NR | 1 |
| Oldham, P | 1 |
| Nichol, PE | 1 |
| Martin, L | 1 |
| Willkens, RF | 1 |
| Sood, OP | 1 |
| Hagroo, A | 1 |
| Vaishnava, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double Blind, Parallel-group Study Of Cardiovascular Safety In Osteoarthritis Or Rheumatoid Arthritis Patients With Or At High Risk For Cardiovascular Disease Comparing Celecoxib With Naproxen And Ibuprofen[NCT00346216] | Phase 4 | 24,081 participants (Actual) | Interventional | 2006-10-04 | Completed | ||
| Placebo-controlled, Dose-response Study of Ibuprofen Effects on Brain Function[NCT02507219] | Phase 2/Phase 3 | 24 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| Salicylic Augmentation in Depression[NCT03152409] | Phase 2 | 74 participants (Anticipated) | Interventional | 2018-11-15 | Recruiting | ||
| A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment[NCT00450658] | Phase 3 | 627 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A Randomized, Double-Blind, Phase 3 Study of the Efficacy and Safety of HZT-501 in Subjects Requiring NSAID Treatment[NCT00450216] | Phase 3 | 906 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| A 4-week, Multicentre, Randomized, Double-blind, Double-dummy, Parallel Group Ambulatory Blood Pressure Monitoring Study to Investigate Whether Treatment With Lumiracoxib 100 mg Once Daily Results in an Improved 24-hour Blood Pressure Profile Compared to [NCT00267176] | Phase 4 | 1,020 participants | Interventional | 2005-11-30 | Completed | ||
| Relevance of the Interaction Between Antihypertensive and Antirheumatic Drugs in a Family Practice[NCT00631514] | Phase 4 | 88 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Ibuprofen 2400 mg in Patients With Osteoarthritis (Study 1)[NCT00269191] | Phase 3 | 528 participants (Actual) | Interventional | 2003-02-05 | Completed | ||
| A 12-Week, Randomized, Placebo- and Active-Comparator-Controlled, Parallel-Group, Double-Blind Study to Assess the Safety and Efficacy of Etoricoxib 30 mg Versus Ibuprofen 2400 mg in Patients With Osteoarthritis (Study 2)[NCT00092755] | Phase 3 | 548 participants (Actual) | Interventional | 2003-04-09 | Completed | ||
| Clinical Evaluation of Condrosulf 800 mg in the Treatment of Symptomatic OA of the Hand: a 6-month, Double-blind, Placebo Controlled Study[NCT00291499] | Phase 3 | 163 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Efficacy Evaluation of Intra-articular Hyaluronic Acid (Sinovial®) vs Synvisc® in the Treatment of Symptomatic Knee Osteoarthritis. A Double-blind, Controlled, Randomised, Parallel-group Non-inferiority Study[NCT00556608] | Phase 4 | 381 participants (Actual) | Interventional | 2007-11-30 | Completed | ||
| Randomized Control Trial Comparing Short-term Outcomes After Direct Anterior and SuperPATH Approaches[NCT03746925] | 100 participants (Anticipated) | Interventional | 2019-09-07 | Recruiting | |||
| Arthroscopic Surgery Versus Non-surgical Treatment of Osteoarthritis of the Knee[NCT00158431] | Phase 3 | 186 participants (Actual) | Interventional | 1999-01-31 | Completed | ||
| Efficacy of Intra-Articular Injection of Etanercept for Moderate and Severe Knee Osteoarthritis[NCT02722772] | 60 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | |||
| Efficacy of Subcutaneous Injection of Etanercept for Moderate and Severe Knee Osteoarthritis[NCT02722811] | 60 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | |||
| Hypoalgesic Effect of Median Nerve Neural Mobilization Versus Ibuprofen Pharmacologic Treatment in Patients With Cervicobrachial Pain[NCT02593721] | Phase 2/Phase 3 | 50 participants (Actual) | Interventional | 2015-07-31 | Completed | ||
| A Prospective, Randomized, Double-blind Study Assessing the Efficacy of Intravenous (IV) Ibuprofen Versus IV Acetaminophen for the Treatment of Pain Following Orthopaedic Low Extremity Surgery[NCT03771755] | 62 participants (Actual) | Interventional | 2017-07-01 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"VAS question How much pain do you have was graded on a scale from 0 to 100 with 0 indicating No pain and 100 indicating Worst possible pain." (NCT00346216)
Timeframe: ITT and MITT Population - Baseline to 42 months
| Intervention | Number of participants (Mean) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline (ITT) N= 8014, 8001, 7928 | Change-Baseline to Mon1 (ITT) N=7382, 7379, 7325 | Change-Baseline to Mon2 (ITT) N=7180, 7090, 7149 | Change-Baseline to Mon4 (ITT) N=6777, 6696, 6740 | Change-Baseline to Mon8 (ITT) N=6230, 6137, 6159 | Change-Baseline to Mon12 (ITT) N=5792, 5696, 5846 | Change-Baseline to Mon18 (ITT) N=5310, 5181. 5246 | Change-Baseline to Mon24 (ITT) N=4818, 4776, 4785 | Change-Baseline to Mon30 (ITT) N=4140, 4069, 4086 | Change-Baseline to Mon36 (ITT) N=3692, 3627, 3635 | Change-Baseline to Mon42 (ITT) N=3469, 3406, 3439 | Baseline (MITT) N=7974, 7954, 7894 | Change-Baseline to Mon1 MITT N=7372, 7367, 7321 | Change-Baseline to Mon2 MITT N=7170, 7078, 7142 | Change-Baseline to Mon4 MITT N=6772, 6686, 6732 | Change-Baseline to Mon8 MITT N=6224, 6128, 6155 | Change-Baseline to Mon12 MITT N=5787, 5689, 5844 | Change-Baseline to Mon18 MITT N=5305, 5175, 5242 | Change-Baseline to Mon24 MITT N=4815, 4769, 4782 | Change-Baseline to Mon30 MITT N=4139, 4067, 4085 | Change-Baseline to Mon36 MITT N=3691, 3623, 3635 | Change-Baseline to Mon42 MITT N=3468, 3404, 3438 | |
| Celecoxib | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.3 | -10.5 | -10.1 | -11.4 | 54.0 | -8.2 | -10.5 | -11.4 | -11.7 | -11.0 | -11.3 | -11.4 | -10.5 | -10.2 | -11.4 |
| Ibuprofen | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 | 54.1 | -9.0 | -10.6 | -11.7 | -12.1 | -11.6 | -11.3 | -11.5 | -11.2 | -10.7 | -11.1 |
| Naproxen | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.4 | -11.3 | -11.6 | -12.1 | 54.1 | -9.9 | -11.1 | -12.3 | -12.1 | -11.9 | -11.7 | -11.3 | -11.3 | -11.6 | -12.1 |
MACE defined as the composite of CV death (including hemorrhagic death), non-fatal MI, non-fatal stroke, hospitalization for UA, revascularization or hospitalization for TIA (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 4.2 | 3.1 |
| Ibuprofen | 4.8 | 3.6 |
| Naproxen | 4.3 | 3.2 |
APTC events are defined as a composite of any of the following events: Death due to CV causes (including cardiac, cerebrovascular, venous thromboembolic, haemorrhagic, other vascular, or unknown cause); Non-fatal MI; Non-fatal stroke (including intracranial hemorrhages, stroke of ischemic or unknown etiology). (NCT00346216)
Timeframe: Intent to Treat (ITT) Population - 30 months; Modified ITT (MITT) Population - 42 months
| Intervention | Percentage of Partcipants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 2.3 | 1.7 |
| Ibuprofen | 2.7 | 1.9 |
| Naproxen | 2.5 | 1.8 |
CSGIE include: Gastroduodenal (GD) hemorrhage, Gastric outlet obstruction, Gastroduodenal, small bowel or large bowel perforation, Large bowel hemorrhage, Small bowel hemorrhage, Acute GI hemorrhage of unknown origin, including presumed small bowel hemorrhage, Symptomatic gastric or duodenal ulcer (NCT00346216)
Timeframe: ITT Population - 30 months; MITT Population - 42 months
| Intervention | Percentage of Participants (Number) | |
|---|---|---|
| ITT (N = 8072, 8040, 7969) | MITT (N = 8030, 7990, 7933) | |
| Celecoxib | 0.7 | 0.3 |
| Ibuprofen | 0.9 | 0.7 |
| Naproxen | 0.7 | 0.7 |
Change in amygdala activation following administration of placebo, 200mg of ibuprofen or 600mg of ibuprofen (NCT02507219)
Timeframe: 3-6 weeks
| Intervention | percent signal change (Mean) | |
|---|---|---|
| Left amygdala | Right amygdala | |
| Ibuprofen, 200mg | 0.21 | 0.23 |
| Ibuprofen, 600mg | 0.23 | 0.17 |
| Placebo | 0.20 | 0.23 |
The secondary efficacy endpoint was the number of subjects with duodenal ulcer at any time throughout the 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 3 |
| Ibuprofen | 9 |
The secondary efficacy endpoint was the number of subjects with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 37 |
| Ibuprofen | 34 |
The primary efficacy endpoint was the number of subjects with upper gastrointestinal (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A subject is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 40 |
| Ibuprofen | 38 |
The secondary efficacy endpoint was the number of subjects developing a NSAID-associated serious GI complication at any time throughout 6 months of treatment. A NSAID-associated serious GI complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or GI bleeding. (NCT00450658)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 0 |
| Ibuprofen | 0 |
The secondary efficacy endpoint was the number of participants with duodenal ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 8 |
| Ibuprofen | 14 |
The primary efficacy endpoint was the number of participants with gastric ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 55 |
| Ibuprofen | 52 |
The secondary efficacy endpoint was the number of participants with UGI (i.e., gastric and/or duodenal) ulcer at any time throughout 24 weeks of treatment. An ulcer was defined as a mucosal break of at least 3 mm in diameter with unequivocal depth. A participant is considered to have completed the study if all scheduled assessments up through the Week 24 visit have been performed. (NCT00450216)
Timeframe: 24 weeks
| Intervention | participants (Number) |
|---|---|
| HZT-501 | 63 |
| Ibuprofen | 61 |
The secondary efficacy endpoint was the number of participants developing a NSAID-associated serious gastrointestinal complication at any time throughout 24 weeks of treatment. A NSAID-associated serious gastrointestinal complication was defined as a perforation of ulcers, gastric outlet obstruction due to ulcers, and/or gastrointestinal bleeding. (NCT00450216)
Timeframe: 24 weeks
| Intervention | particpants (Number) |
|---|---|
| HZT-501 | 3 |
| Ibuprofen | 0 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
"Functional Index for Hand Osteoarthritis (Dreiser's Index). Range 0-30 Patients reported the severity of their symptoms by answering a set of 10 questions. Severity was rated on a numerical scale (0 = possible without difficulty, 1 = possible with slight difficulty, 2 =possible with great difficulty, and 3 = impossible), being 30 points the worst possible pain score.~Change calculated as difference between the month 6 value and baseline value~Target hand defined as the patient's most symptomatic hand or, when both hands were equally painful, the patient's dominant hand" (NCT00291499)
Timeframe: 6 month
| Intervention | score on a scale (Mean) |
|---|---|
| Chondroitin 4&6 Sulfate (Condrosulf) | -2.9 |
| Placebo | -0.7 |
Intensity of global spontaneous pain is evaluated by the patient himself on a Huskisson's visual analogue scale (VAS) of 100 mm. 0=no pain 100=max pain Change calculated as difference between Month 6 value and baseline value target hand is defined as the patient's most symptomatic hand or, when both hands were equally painful, the patient's dominant hand. (NCT00291499)
Timeframe: 6 months
| Intervention | mm (Mean) |
|---|---|
| Chondroitin 4&6 Sulfate (Condrosulf) | -20 |
| Placebo | -11.3 |
"Grip strength determined on both hands using a Jamar dynamometer.Patients were required to grip the dynamometer handle and squeeze as hard as possible according to their individual pain limits. The right hand grip was measured first, then the left; this procedure was performed 3 times. The mean value of these 3 measurements was recorded.~Change calculated as difference between the month 6 value and baseline value" (NCT00291499)
Timeframe: 6 months
| Intervention | Kg/cm^2 (Mean) |
|---|---|
| Chondroitin 4&6 Sulfate (Condrosulf) | 2.5 |
| Placebo | 0.6 |
Change in morning stiffness duration calculated as the difference between the month 6 value and the baseline value (NCT00291499)
Timeframe: 6 months
| Intervention | minutes (Mean) |
|---|---|
| Chondroitin 4&6 Sulfate (Condrosulf) | -4.8 |
| Placebo | 0.3 |
Total consumption (between ^baseline and month 6) of paracetamol (500 mg tablets) reported by the patients on a daily diary (NCT00291499)
Timeframe: 6 months
| Intervention | tablets/week (Mean) |
|---|---|
| Chondroitin 4&6 Sulfate (Condrosulf) | 1.9 |
| Placebo | 2.0 |
19 reviews available for ibuprofen and Osteoarthritis
| Article | Year |
|---|---|
Toxic, Genotoxic and Teratogenic Effects of Ibuprofen and its Derivatives.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; DNA Damage; Humans; Ibuprof | 2023 |
Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort Study.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Back Pain; Cohort Studies; COVID-19; COVID-1 | 2023 |
A systematic review and meta-analysis of oxaceprol in the management of osteoarthritis: An evidence from randomized parallel-group controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Diclofenac; Humans; Hydroxyproline; I | 2019 |
Risk of upper gastrointestinal ulcers in patients with osteoarthritis receiving single-tablet ibuprofen/famotidine versus ibuprofen alone: pooled efficacy and safety analyses of two randomized, double-blind, comparison trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Combinations; Duodenal Ulcer; Famot | 2014 |
HZT-501 (DUEXIS(®); ibuprofen 800 mg/famotidine 26.6 mg) gastrointestinal protection in the treatment of the signs and symptoms of rheumatoid arthritis and osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Drug Combinations | 2012 |
Interventions for the management of temporomandibular joint osteoarthritis.
Topics: Anti-Inflammatory Agents; Betamethasone; Diclofenac; Glucosamine; Humans; Hyaluronic Acid; Ibuprofen | 2012 |
[Meta-analysis of the efficacy of adenosylmethionine and oxaceprol in the treatment of osteoarthritis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Data Interpretation, Statistical; Dic | 2002 |
[Meta-analysis on the effect and adverse reaction on patients with osteoarthritis and rheumatoid arthritis treated with non-steroidal anti-inflammatory drugs].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; China; Diclofenac; Humans | 2003 |
[Treatment for inflammation related pain--COX-2 inhibitors knocking on the door].
Topics: Acetaminophen; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Dysmenorrhea; Female; Humans; Ibupr | 2004 |
Review of ibuprofen for osteoarthritis.
Topics: Acetaminophen; Anti-Inflammatory Agents; Aspirin; Clinical Trials as Topic; Diflunisal; Drug Toleran | 1984 |
Diclofenac sodium: a review of its pharmacological properties and therapeutic use in rheumatic diseases and pain of varying origin.
Topics: Adult; Animals; Arthritis, Rheumatoid; Aspirin; Cyclooxygenase Inhibitors; Diclofenac; Drug Interact | 1980 |
Use of carprofen for the treatment of pain and inflammation in dogs.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; | 1997 |
Non-NSAID pharmacologic treatment options for the management of chronic pain.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal | 1998 |
[Brufen on the eve of the 21st century].
Topics: Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; C | 1998 |
Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cyclooxyg | 1999 |
Celecoxib clinical profile.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2000 |
Glucosamine therapy compared to ibuprofen for joint pain.
Topics: Arthralgia; Glucosamine; Humans; Ibuprofen; Osteoarthritis; Treatment Outcome | 2002 |
Rheumatoid arthritis: an overview.
Topics: Adult; Arthritis; Arthritis, Reactive; Arthritis, Rheumatoid; Aspirin; Diagnosis, Differential; Fema | 1976 |
[Statistical meta-analysis of multicenter clinical studies of ibuprofen with regard to cohort size].
Topics: Cohort Studies; Dose-Response Relationship, Drug; Humans; Ibuprofen; Meta-Analysis as Topic; Osteoar | 1991 |
129 trials available for ibuprofen and Osteoarthritis
| Article | Year |
|---|---|
Topics: Adult; Arthritis, Rheumatoid; Cardiovascular Diseases; Celecoxib; Double-Blind Method; Drug Therapy, | 2017 |
The Risk of Major NSAID Toxicity with Celecoxib, Ibuprofen, or Naproxen: A Secondary Analysis of the PRECISION Trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase 2 Inhibito | 2017 |
Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement)
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Blood Pressure; Celecoxib; Coronary | 2017 |
Differences in Safety of Nonsteroidal Antiinflammatory Drugs in Patients With Osteoarthritis and Patients With Rheumatoid Arthritis: A Randomized Clinical Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2018 |
Randomised clinical trial: gastrointestinal events in arthritis patients treated with celecoxib, ibuprofen or naproxen in the PRECISION trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Aspi | 2018 |
Derivation and Validation of a Major Toxicity Risk Score Among Nonsteroidal Antiinflammatory Drug Users Based on Data From a Randomized Controlled Trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cardiovascular Diseases; Celec | 2019 |
NSAIDs are associated with lower depression scores in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Depression; Doub | 2013 |
NSAIDs are associated with lower depression scores in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Depression; Doub | 2013 |
NSAIDs are associated with lower depression scores in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Depression; Doub | 2013 |
NSAIDs are associated with lower depression scores in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Depression; Doub | 2013 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Gastroprotective efficacy and safety of single-tablet ibuprofen/famotidine vs ibuprofen in older persons.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Age | 2015 |
Clinical trial: comparison of ibuprofen-phosphatidylcholine and ibuprofen on the gastrointestinal safety and analgesic efficacy in osteoarthritic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non- | 2008 |
Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Blood Pressure Monitoring, Ambulatory | 2008 |
Interaction between antihypertensives and NSAIDs in primary care: a controlled trial.
Topics: Acetaminophen; Aged; Amlodipine; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; B | 2008 |
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors.
Topics: Aged; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Humans; Ibuprofen; | 2010 |
The effects of lumiracoxib 100 mg once daily vs. ibuprofen 600 mg three times daily on the blood pressure profiles of hypertensive osteoarthritis patients taking different classes of antihypertensive agents.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Cyclooxygen | 2010 |
Effects of superpulsed low-level laser therapy on temporomandibular joint pain.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Humans; Ibu | 2010 |
Palmitoylethanolamide versus a nonsteroidal anti-inflammatory drug in the treatment of temporomandibular joint inflammatory pain.
Topics: Adult; Amides; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; Double-Blind Method; Endocannabi | 2012 |
Incidence of gastroduodenal ulcers associated with valdecoxib compared with that of ibuprofen and diclofenac in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Cyclo | 2002 |
Complementary studies of the gastrointestinal safety of the cyclo-oxygenase-2-selective inhibitor etoricoxib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Cyclooxygenase 2; Cyclooxygenase | 2003 |
Short report: ibuprofen versus glucosamine sulfate. Treating osteoarthritis pain.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Gl | 2003 |
Therapeutic arthritis research and gastrointestinal event trial of lumiracoxib - study design and patient demographics.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 In | 2004 |
Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitor | 2004 |
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
Topics: Aged; Celecoxib; Cyclooxygenase Inhibitors; Diclofenac; Female; Humans; Ibuprofen; Incidence; Male; | 2004 |
Using n-of-1 trials as a clinical tool to improve prescribing.
Topics: Acetaminophen; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Attention Deficit Disorder with Hy | 2005 |
Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; | 2005 |
Valdecoxib is associated with improved dyspepsia-related health compared with nonspecific NSAIDs in patients with osteoarthritis or rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cyclooxygenase Inhibitors; Diclofena | 2005 |
Comparative effect of nimesulide and ibuprofen on the urinary levels of collagen type II C-telopeptide degradation products and on the serum levels of hyaluronan and matrix metalloproteinases-3 and -13 in patients with flare-up of osteoarthritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Collagen; Collagen Typ | 2005 |
A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Chemotherapy, Adjuva | 2007 |
Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen.
Topics: Acid-Base Equilibrium; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, | 2006 |
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Celecoxib; Double-Blind Method; Drug Adminis | 2006 |
Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Arnica; Double-Blind Method; Finge | 2007 |
Cardiovascular outcomes in high risk patients with osteoarthritis treated with ibuprofen, naproxen or lumiracoxib.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Cyclooxygenase 2 In | 2007 |
Effect of risk factors on complicated and uncomplicated ulcers in the TARGET lumiracoxib outcomes study.
Topics: Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Diclof | 2007 |
A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30 mg and ibuprofen 2400 mg for the treatment of patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Cyclooxygenase Inhibitors; Double-Blind Method; Etoricoxib; Female; | 2007 |
[Efficacy of ibuprofen (nurofen gel) ultraphonophoresis for pain relief in osteoarthrosis].
Topics: Administration, Cutaneous; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Drug Administration | 2007 |
[Treatment of osteoarthrosis with a new nonsteroidal anti-inflammatory agent, carprofen].
Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Clinical | 1984 |
Four-way, multicenter, crossover trial of ibuprofen, fenoprofen calcium, naproxen, and tolmetin sodium in osteoarthritis: comparative clinical profiles.
Topics: Adult; Aged; Aspirin; Clinical Trials as Topic; Double-Blind Method; Drug Tolerance; Female; Fenopro | 1983 |
A multi-centre study of tiaprofenic acid ('Surgam') and five comparative drugs in rheumatoid arthritis and osteoarthritis in general practice.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthriti | 1983 |
Comparison of suprofen and ibuprofen in the treatment of pain secondary to osteoarthritis.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Ibuprofen; M | 1983 |
[Comparative clinical evaluation of the preparations Feldene-Pfizer and Ibuprofen-Polfa in the treatment of patients with osteoarthritis].
Topics: Anti-Inflammatory Agents; Clinical Trials as Topic; Humans; Ibuprofen; Osteoarthritis; Piroxicam; Th | 1983 |
A study of naproxen and ibuprofen in patients with osteoarthritis seen in general practice. The Manchester General Practitioner Group.
Topics: Aged; Clinical Trials as Topic; Female; Humans; Ibuprofen; Male; Middle Aged; Naproxen; Osteoarthrit | 1984 |
Review of ibuprofen for osteoarthritis.
Topics: Acetaminophen; Anti-Inflammatory Agents; Aspirin; Clinical Trials as Topic; Diflunisal; Drug Toleran | 1984 |
Is sustained-release ibuprofen as effective as piroxicam? A comparison in patients with osteoarthritis.
Topics: Aged; Clinical Trials as Topic; Delayed-Action Preparations; Digestive System; Female; Humans; Ibupr | 1984 |
Symptomatic osteoarthritis in the elderly: multicentre comparative study of sulindac and ibuprofen.
Topics: Aged; Female; Humans; Ibuprofen; Indenes; Male; Middle Aged; Osteoarthritis; Sulindac | 1984 |
Carprofen in osteoarthrosis.
Topics: Adult; Anti-Inflammatory Agents; Carbazoles; Clinical Trials as Topic; Double-Blind Method; Drug Adm | 1982 |
A study of sulindac versus ibuprofen in elderly patients with osteoarthritis.
Topics: Aged; Female; Humans; Ibuprofen; Indenes; Male; Osteoarthritis; Sulindac | 1983 |
Diclofenac and ibuprofen in rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Female; Humans; Ib | 1980 |
Benoxaprofen in the treatment of osteoarthritis--a comparison with ibuprofen.
Topics: Adult; Aged; Anti-Inflammatory Agents; Benzoxazoles; Clinical Trials as Topic; Double-Blind Method; | 1980 |
Long-term safety of benoxaprofen.
Topics: Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Benzoxazoles; Blood Urea Nitrogen; C | 1980 |
A comparative study of benoxaprofen and ibuprofen in osteoarthritis in general practice.
Topics: Adult; Age Factors; Aged; Alkaline Phosphatase; Anti-Inflammatory Agents; Benzoxazoles; Clinical Tri | 1980 |
Long-term treatment of symptomatic osteoarthritis with benoxaprofen. Double-blind comparison with aspirin and ibuprofen.
Topics: Adult; Aged; Anti-Inflammatory Agents; Aspirin; Benzoxazoles; Clinical Trials as Topic; Double-Blind | 1980 |
[Controlled clinical study of SAMe (S-adenosylmethionine) administered orally in degenerative osteoarticular pathology].
Topics: Administration, Oral; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Ibuprofen; Male | 1980 |
Arthritis: anti-inflammatory drugs in practice.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Apazone; Arthritis, Rheumatoid; As | 1981 |
A study of the efficacy and tolerability of diclofenac and ibuprofen in osteoarthritis of the hip.
Topics: Aged; Clinical Trials as Topic; Diclofenac; Double-Blind Method; Female; Hip Joint; Humans; Ibuprofe | 1981 |
[Use of ibuprofen cream in ambulatory orthopedic patients. Double-blind comparison with placebo].
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Ibuprofen; Male; Middle | 1982 |
Short-term treatment of osteoarthritis: a comparison of sodium meclofenamate and ibuprofen.
Topics: Aged; Anti-Inflammatory Agents; Female; Hip Joint; Humans; Ibuprofen; Knee Joint; Male; Meclofenamic | 1982 |
Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulphate in the management of osteoarthrosis of the knee in out-patients.
Topics: Aged; Double-Blind Method; Female; Glucosamine; Humans; Ibuprofen; Knee Joint; Male; Middle Aged; Os | 1982 |
A randomized comparison between sulindac and ibuprofen in osteoarthritis of the aged.
Topics: Aged; Female; Humans; Ibuprofen; Indenes; Male; Osteoarthritis; Random Allocation; Sulindac | 1981 |
Glycosaminoglycan polysulfuric acid (GAGPS) in osteoarthritis of the knee.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Glycosaminoglycans; Huma | 1995 |
[A multicenter evaluation of efficacy and tolerance in the local treatment with dolgit cream of patients with osteoarthrosis].
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Drug | 1995 |
Investigation into the duration of action of sustained-release ibuprofen in osteoarthritis and rheumatoid arthritis.
Topics: Aged; Arthritis, Rheumatoid; Delayed-Action Preparations; Double-Blind Method; Female; Humans; Ibupr | 1994 |
[Ibuprofen 800 mg in the treatment of arthrosis of the fingers or rhizarthrosis].
Topics: Adult; Aged; Ambulatory Care; Data Interpretation, Statistical; Double-Blind Method; Female; Finger | 1993 |
Evaluation of the renal protective effect of misoprostol in elderly, osteoarthritic patients at risk for nonsteroidal anti-inflammatory drug-induced renal dysfunction.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Dinoprostone; Double-Blind Method; Female; Glomerular | 1993 |
A controlled study comparing the effects of nabumetone, ibuprofen, and ibuprofen plus misoprostol on the upper gastrointestinal tract mucosa.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Endoscopy, Digestive | 1993 |
Safety experience with nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Diclofenac; | 1993 |
Efficacy and safety of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in the elderly.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; | 1993 |
Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Diclofenac; | 1993 |
Ibuprofen and diclofenac sodium in the treatment of osteoarthritis: a comparative trial of two once-daily sustained-release NSAID formulations.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; | 1996 |
[Double-blind comparative study of the effectiveness and tolerance of 900 mg dexibuprofen and 150 mg diclofenac sodium in patients with painful gonarthrosis].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Dose-Response Relationship, Drug; | 1997 |
Efficacy and safety of glucosamine sulfate versus ibuprofen in patients with knee osteoarthritis.
Topics: Adult; Aged; Antirheumatic Agents; Female; Glucosamine; Humans; Ibuprofen; Knee; Male; Middle Aged; | 1998 |
A decision analysis model in the evaluation of NSAIDs in a managed care setting: a case study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Butanones; Decision Tre | 1994 |
[Structum (chondroitin sulfate)--a new agent for the treatment of osteoarthrosis].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Chondroitin Sulfates; Female; Humans; Ibuprofen; Knee | 1999 |
A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoscopy Study Group.
Topics: Aged; Aged, 80 and over; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; D | 1999 |
Comparison of the responsiveness and relative effect size of the western Ontario and McMaster Universities Osteoarthritis Index and the short-form Medical Outcomes Study Survey in a randomized, clinical trial of osteoarthritis patients.
Topics: Activities of Daily Living; Aged; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Effe | 1999 |
A randomized, placebo-controlled, cross-over study of ginger extracts and ibuprofen in osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cross-Over Studies; Double- | 2000 |
[Specific cyclo-oxygenase inhibitors. 2. Gastric toxicity?].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase Inhi | 2000 |
A randomized trial of the efficacy and tolerability of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis. Rofecoxib/Ibuprofen Comparator Study Group.
Topics: Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; | 2000 |
Preliminary experiences with a single-patient trials service in general practice.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, N | 2000 |
A randomized trial measuring fecal blood loss after treatment with rofecoxib, ibuprofen, or placebo in healthy subjects.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chromium Radioisotopes; Cyclooxygenase 2; Cyclooxyge | 2000 |
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; | 2000 |
Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; | 2000 |
Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; | 2000 |
Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; | 2000 |
Minimal perceptible clinical improvement with the Western Ontario and McMaster Universities osteoarthritis index questionnaire and global assessments in patients with osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; | 2000 |
Pharmacokinetics, safety, and tolerability of BAY 12-9566 and nonsteroidal anti-inflammatory agents (naproxen, ibuprofen) during coadministration in patients with osteoarthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Area Under Curve; Biphe | 2001 |
Evaluation of glucosamine sulfate compared to ibuprofen for the treatment of temporomandibular joint osteoarthritis: a randomized double blind controlled 3 month clinical trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Female; Glucosamine; Humans; Ib | 2001 |
Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials.
Topics: Aged; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Double-Blind Method; | 2001 |
Effects of non-steroidal anti-inflammatory drugs on hypertension control using angiotensin converting enzyme inhibitors and thiazide diuretics.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive | 2001 |
A controlled clinical study comparing sulindac with ibuprofen and aspirin in the treatment of musculo-skeletal diseases.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; | 1979 |
Ibuprofen in osteoarthritis.
Topics: Activities of Daily Living; Aspirin; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Dextro | 1977 |
Diflunisal: six-month experience in osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Trials as Topic; Drug Evaluation; Fluorob | 1977 |
Butacote and ibuprofen: a comparative assessment in rheumatic diseases in general practice.
Topics: Arthritis, Rheumatoid; Clinical Trials as Topic; Family Practice; Female; Humans; Ibuprofen; Male; O | 1977 |
A double-blind trial of feprazone in osteoarthritis of the hip.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Female; Feprazone; Hip Joint; Humans; Ibuprofen | 1977 |
Comparative study of sulindac (Clinoril) and ibuprofen (Brufen) in osteoarthrosis.
Topics: Aged; Benzylidene Compounds; Clinical Trials as Topic; Female; Humans; Ibuprofen; Indenes; Male; Mid | 1978 |
Diflunisal in the treatment of osteoarthrosis: a double-blind study comparing diflunisal with ibuprofen.
Topics: Adult; Age Factors; Aged; Analgesics; Biphenyl Compounds; Bone Diseases; Clinical Trials as Topic; D | 1978 |
[Therapeutic research on osteoarthrosis in the aged: controlled trial of indoprofen and ibuprofen].
Topics: Age Factors; Aged; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Ibuprofen; Indoprofen; | 1978 |
[Double-blind comparative study of indoprofen and ibuprofen in patients with osteoarthrosis].
Topics: Administration, Oral; Adult; Aged; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Ibupro | 1979 |
A comparative clinical trial of diflunisal and ibuprofen in the control of pain in osteoarthritis.
Topics: Clinical Trials as Topic; Diflunisal; Double-Blind Method; Female; Hip Joint; Humans; Ibuprofen; Kne | 1979 |
Analysis of the Brazilian literature on diclofenac sodium (Voltarol).
Topics: Arthritis, Rheumatoid; Brazil; Clinical Trials as Topic; Diclofenac; Drug Tolerance; Female; Humans; | 1979 |
A comparative study of floctafenine (Idarac) and ibuprofen in the treatment of osteoarthrosis.
Topics: Aged; Female; Humans; Ibuprofen; Male; Middle Aged; Osteoarthritis; Quinolines | 1978 |
A comparative study of azapropazone and ibuprofen in the treatment of osteoarthrosis of the knee.
Topics: Adult; Aged; Apazone; Clinical Trials as Topic; Drug Evaluation; Female; Humans; Ibuprofen; Knee Joi | 1976 |
Sulindac in osteoarthrosis of the hip.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Drug Evaluation; Fem | 1976 |
Response of osteoarthritis to ibuprofen or flurbiprofen.
Topics: Aged; Clinical Trials as Topic; Drug Evaluation; Female; Flurbiprofen; Humans; Ibuprofen; Male; Midd | 1976 |
A six-month double-blind trial of ibuprofen and indomethacin in osteoarthritis.
Topics: Adult; Central Nervous System; Clinical Trials as Topic; Digestive System; Female; Humans; Ibuprofen | 1975 |
Ibuprofen and visual function. Prospective evaluation.
Topics: Adult; Aged; Aspirin; Female; Humans; Ibuprofen; Long-Term Care; Male; Middle Aged; Osteoarthritis; | 1975 |
Ibuprofen versus buffered phenylbutazone in the treatment of osteoarthritis: double-blind trial.
Topics: Alanine Transaminase; Clinical Trials as Topic; Drug Evaluation; Humans; Ibuprofen; Osteoarthritis; | 1975 |
Treatment of knee osteoarthritis: relationship of clinical features of joint inflammation to the response to a nonsteroidal antiinflammatory drug or pure analgesic.
Topics: Acetaminophen; Adult; Aged; Analysis of Variance; Dose-Response Relationship, Drug; Double-Blind Met | 1992 |
Variability in the disposition of ibuprofen enantiomers in osteoarthritis patients.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administ | 1992 |
Correlation of serum concentrations of ibuprofen stereoisomers with clinical response in the treatment of hip and knee osteoarthritis.
Topics: Adult; Disability Evaluation; Female; Hip Joint; Humans; Ibuprofen; Knee Joint; Male; Middle Aged; O | 1992 |
[Gitadyl versus ibuprofen in patients with osteoarthrosis. The result of a double-blind, randomized cross-over study].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Double-Blind Method; Drug Evaluation; Humans; Ibupro | 1991 |
[Publication of negative test results].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Ibuprofen; Osteoarthritis | 1991 |
[Gitadyl is not an alternative to ibuprofen in osteoarthrosis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Evaluation; Humans; Ibuprofen; Osteoarthritis; Plant E | 1991 |
[Gitadyl versus ibuprofen].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Drug Evaluation; Humans; Ibuprofen; Osteoarthritis | 1991 |
[Statistical meta-analysis of multicenter clinical studies of ibuprofen with regard to cohort size].
Topics: Cohort Studies; Dose-Response Relationship, Drug; Humans; Ibuprofen; Meta-Analysis as Topic; Osteoar | 1991 |
[Real time collection of pain profile in treatment with ibuprofen].
Topics: Adult; Data Collection; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Huma | 1991 |
[Experiences with 800 mg ibuprofen retard in ambulatory patients with activated osteoarthrosis and extra-articular rheumatic manifestations].
Topics: Adult; Aged; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administration Sche | 1991 |
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
Topics: Acetaminophen; Chronic Disease; Double-Blind Method; Female; Humans; Ibuprofen; Knee Joint; Locomoti | 1991 |
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
Topics: Acetaminophen; Chronic Disease; Double-Blind Method; Female; Humans; Ibuprofen; Knee Joint; Locomoti | 1991 |
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
Topics: Acetaminophen; Chronic Disease; Double-Blind Method; Female; Humans; Ibuprofen; Knee Joint; Locomoti | 1991 |
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
Topics: Acetaminophen; Chronic Disease; Double-Blind Method; Female; Humans; Ibuprofen; Knee Joint; Locomoti | 1991 |
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
Topics: Acetaminophen; Chronic Disease; Double-Blind Method; Female; Humans; Ibuprofen; Knee Joint; Locomoti | 1991 |
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
Topics: Acetaminophen; Chronic Disease; Double-Blind Method; Female; Humans; Ibuprofen; Knee Joint; Locomoti | 1991 |
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
Topics: Acetaminophen; Chronic Disease; Double-Blind Method; Female; Humans; Ibuprofen; Knee Joint; Locomoti | 1991 |
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
Topics: Acetaminophen; Chronic Disease; Double-Blind Method; Female; Humans; Ibuprofen; Knee Joint; Locomoti | 1991 |
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
Topics: Acetaminophen; Chronic Disease; Double-Blind Method; Female; Humans; Ibuprofen; Knee Joint; Locomoti | 1991 |
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
Topics: Acetaminophen; Chronic Disease; Double-Blind Method; Female; Humans; Ibuprofen; Knee Joint; Locomoti | 1991 |
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
Topics: Acetaminophen; Chronic Disease; Double-Blind Method; Female; Humans; Ibuprofen; Knee Joint; Locomoti | 1991 |
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
Topics: Acetaminophen; Chronic Disease; Double-Blind Method; Female; Humans; Ibuprofen; Knee Joint; Locomoti | 1991 |
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
Topics: Acetaminophen; Chronic Disease; Double-Blind Method; Female; Humans; Ibuprofen; Knee Joint; Locomoti | 1991 |
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
Topics: Acetaminophen; Chronic Disease; Double-Blind Method; Female; Humans; Ibuprofen; Knee Joint; Locomoti | 1991 |
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
Topics: Acetaminophen; Chronic Disease; Double-Blind Method; Female; Humans; Ibuprofen; Knee Joint; Locomoti | 1991 |
Comparison of an antiinflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee.
Topics: Acetaminophen; Chronic Disease; Double-Blind Method; Female; Humans; Ibuprofen; Knee Joint; Locomoti | 1991 |
Double-blind randomized clinical trial on imidazole salicylate vs ibuprofen in osteoarthritis.
Topics: Adult; Aged; Double-Blind Method; Female; Humans; Ibuprofen; Imidazoles; Knee Joint; Male; Middle Ag | 1991 |
Fish oil in osteoarthritis.
Topics: Aged; Aged, 80 and over; Drug Therapy, Combination; Eicosapentaenoic Acid; Female; Humans; Ibuprofen | 1989 |
Topical non-steroidal anti-inflammatory drugs.
Topics: Administration, Oral; Administration, Topical; Clinical Trials as Topic; Double-Blind Method; Humans | 1989 |
["Morning type" and "evening type" in activated osteoarthritis. Analysis and practice-related conclusions of an open, multicenter study with ibuprofen].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Circadian Rhythm; Clinical Trials as Topic; Female; Huma | 1989 |
The effect of etodolac administration on renal function in patients with arthritis.
Topics: Acetates; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Blood Urea | 1986 |
[Pain profile in activated osteoarthritis. Results of an open, multicenter study with ibuprofen].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Female; Humans; Ibuprofen; Mal | 1988 |
Mefenamic acid versus ibuprofen in osteoarthritis--a double-blind cross-over study.
Topics: Clinical Trials as Topic; Double-Blind Method; Female; Humans; Ibuprofen; Male; Mefenamic Acid; Oste | 1986 |
Comparison of a standard ibuprofen treatment regimen with a new ibuprofen/paracetamol/codeine combination in chronic osteo-arthritis.
Topics: Acetaminophen; Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Codeine; Double-Blind Metho | 1987 |
Multicenter double-blind randomized clinical trial of imidazole salicylate versus ibuprofen in patients with osteoarthrosis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Clinical Trials as Topic; Double-Blind Method; Female; Humans | 1987 |
Double-blind clinical trial of S-adenosylmethionine versus ibuprofen in the treatment of osteoarthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Double-Blind Method; | 1987 |
International experiences with diclofenac in osteoarthritis.
Topics: Aspirin; Clinical Trials as Topic; Diclofenac; Diflunisal; Double-Blind Method; Gastrointestinal Dis | 1986 |
Renal safety of two analgesics used over the counter: ibuprofen and aspirin.
Topics: Adult; Aged; Arthritis, Rheumatoid; Aspirin; Blood Urea Nitrogen; Clinical Trials as Topic; Creatini | 1986 |
Clinical benefits and comparative safety of piroxicam. Analysis of worldwide clinical trials data.
Topics: Adult; Age Factors; Aged; Clinical Trials as Topic; Female; Gastrointestinal Hemorrhage; Humans; Ibu | 1986 |
Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis.
Topics: Aged; Clinical Trials as Topic; Double-Blind Method; Female; Hip Joint; Humans; Ibuprofen; Knee Join | 1985 |
A controlled comparison of tiaprofenic acid and ibuprofen in osteoarthritis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Double-Blind Method; | 1985 |
Worldwide clinical safety experience with diclofenac.
Topics: Aspirin; Clinical Trials as Topic; Diclofenac; France; Humans; Ibuprofen; Japan; Osteoarthritis; Rhe | 1985 |
Comparison of anti-rheumatic effects of phenylbutazone and ibuprofen.
Topics: Analgesics; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Clinical Trials as Topic; Female; Human | 1974 |
73 other studies available for ibuprofen and Osteoarthritis
| Article | Year |
|---|---|
Effects of ibuprofen on gene expression in chondrocytes from patients with osteoarthritis as determined by RNA-Seq.
Topics: Cells, Cultured; Chondrocytes; Gene Expression; Humans; Ibuprofen; Osteoarthritis; RNA-Seq | 2021 |
Gelatin-glucosamine hydrochloride/crosslinked-cyclodextrin metal-organic frameworks@IBU composite hydrogel long-term sustained drug delivery system for osteoarthritis treatment.
Topics: Cyclodextrins; Drug Delivery Systems; Gelatin; Glucosamine; Humans; Hydrogels; Ibuprofen; Metal-Orga | 2022 |
Interactions of Nonsteroidal Antiinflammatory Drugs and Aspirin and Risk of Cardiovascular Disease in Patients With Osteoarthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Humans; Ibuprofen; Naprox | 2023 |
TLR4, RAGE, and p-JNK/JNK mediated inflammatory aggression in osteoathritic human chondrocytes are counteracted by redox-sensitive phenolic olive compounds: Comparison with ibuprofen.
Topics: Aged; Aldehydes; Biomarkers; Cartilage, Articular; Cell Adhesion; Cell Survival; Chondrocytes; Femal | 2020 |
Ibuprofen-loaded calcium phosphate granules: A new bone substitute for local relieving symptoms of osteoarthritis.
Topics: Animals; Bone Substitutes; Calcium Phosphates; Ibuprofen; Mice; Osteoarthritis | 2021 |
Ibuprofen-based advanced therapeutics: breaking the inflammatory link in cancer, neurodegeneration, and diseases.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Female; Humans; Ibuprofen; Neoplasms | 2021 |
NSAIDs relieve osteoarthritis (OA) pain, but cardiovascular safety in question even for diclofenac, ibuprofen, naproxen, and celecoxib: what are the alternatives?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Diclofenac; Humans; Ibuprofen; Naproxen; Network | 2017 |
Efficacy and safety of diclofenac in osteoarthritis: Results of a network meta-analysis of unpublished legacy studies.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Diclofenac; Female; Humans; Ibuprofen; Male; Middle Aged; N | 2017 |
Polyunsaturated fatty acids influence inflammatory markers in a cellular model for canine osteoarthritis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Biomarkers; Chondrocytes; Docosa | 2018 |
Evaluation of the effect of polyphenol of escin compared with ibuprofen and dexamethasone in synoviocyte model for osteoarthritis: an in vitro study.
Topics: Animals; Anti-Inflammatory Agents; Cattle; Cyclooxygenase 2; Dexamethasone; Dinoprostone; Escin; Fem | 2018 |
There seems to be similar improvement in pain and mouth opening limitation when comparing glucosamine supplements with a placebo or ibuprofen in patients with temporomandibular joint osteoarthritis.
Topics: Glucosamine; Humans; Ibuprofen; Mouth; Osteoarthritis; Pain; Temporomandibular Joint | 2018 |
Intra-articular mucilages: behavioural and histological evaluations for a new model of articular pain.
Topics: Althaea; Analgesics; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Flax; Freund's Adjuvan | 2019 |
Budget impact modeling for a single-tablet formulation of ibuprofen and famotidine for prevention of upper gastrointestinal ulcers in patients with osteoarthritis and/or rheumatoid arthritis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Arthritis, Rheumatoid; Drug Combinations | 2013 |
Ibuprofen-loaded porous microspheres suppressed the progression of monosodium iodoacetate-induced osteoarthritis in a rat model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Cell Proliferation; Chond | 2016 |
Therapeutic mechanisms of ibuprofen, prednisone and betamethasone in osteoarthritis.
Topics: Aggrecans; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Betamethasone; Cell Li | 2017 |
Therapy: Cardiovascular safety of celecoxib, naproxen and ibuprofen.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular System; Celecoxib; Clinical Trials as Topic; | 2017 |
Macroscopic small bowel mucosal injury caused by chronic nonsteroidal anti-inflammatory drugs (NSAID) use as assessed by capsule endoscopy.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Capsule Endoscopy; Cyclooxygenase 2 Inhibitors | 2010 |
Periorbital edema associated with separate courses of ibuprofen and naproxen.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Edema; Eye Diseases; Female; Humans; Ibu | 2010 |
The effects of NSAIDs on types I, II, and III collagen metabolism in a rat osteoarthritis model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cartilage, Articular; Celecoxib; Chondrocytes; Col | 2012 |
Flavocoxid inhibits phospholipase A2, peroxidase moieties of the cyclooxygenases (COX), and 5-lipoxygenase, modifies COX-2 gene expression, and acts as an antioxidant.
Topics: Acetaminophen; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Arachidonate 5-Lipoxy | 2011 |
A fixed-dose combination ibuprofen and famotidine (Duexis).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Drug Combinations; Duodenal Ulcer; F | 2011 |
Selective COX-2 inhibitor ameliorates osteoarthritis by repressing apoptosis of chondrocyte.
Topics: Animals; Apoptosis; Cartilage, Articular; Celecoxib; Chondrocytes; Collagen Type II; Cyclooxygenase | 2012 |
Pseudodementia associated with use of ibuprofen.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Factitious Disorders; Humans; Ibuprofen; Male; Osteoa | 2003 |
[Effective NSAID as optically pure isomer. Therapy of arthrosis becomes more tolerable].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Humans; Ibuprofen; Osteoarthritis; Randomized Controlled Tr | 2002 |
Key questions concerning paracetamol and NSAIDs for OA.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; I | 2003 |
Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Aspirin; Dose-R | 2003 |
Fixed drug eruption to ibuprofen in daughter and father.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Diagnosis, Differential; Drug Eruptions; | 2003 |
Longer use of COX-2-specific inhibitors compared to nonspecific nonsteroidal antiinflammatory drugs: a longitudinal study of 3639 patients in community practice.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Celecoxib; Community Health Services | 2004 |
Evidence in practice--number 3: Cox 2 inhibitors.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Evidence-Based Medic | 2004 |
Study of interaction between ibuprofen and nicotinamide using differential scanning calorimetry, spectroscopy, and microscopy and formulation of a fast-acting and possibly better ibuprofen suspension for osteoarthritis patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Calorimetry, Differential Scanning; Chemistry, Pharmaceutic | 2005 |
Management of nonsteroidal, anti-inflammatory, drug-associated dyspepsia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cyclooxygenase 2 Inhibitors; Dyspepsia; | 2005 |
Australia: the N of 1 trial, an underappreciated research method.
Topics: Acetaminophen; Aged; Attention Deficit Disorder with Hyperactivity; Australia; Child; Child, Prescho | 2006 |
Treating osteoarthritis in the elderly: should recent data on NSAIDs change our way of practice?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2 Inhibitors; Databases, Factual; Dicl | 2007 |
[Ibuprofenlysinate in the treatment of osteoarthrosis].
Topics: Adult; Aged; Female; Humans; Ibuprofen; Lysine; Male; Middle Aged; Osteoarthritis | 1983 |
[Sulindac in osteoarthrosis].
Topics: Adult; Aged; Back Pain; Female; Humans; Ibuprofen; Indenes; Knee Joint; Lumbar Vertebrae; Male; Midd | 1980 |
Inflammatory involvement in rabbit knee following immobilization and resulting in osteoarthritis.
Topics: Acetylglucosaminidase; Animals; Dinoprostone; Ibuprofen; Immobilization; Knee Joint; Models, Biologi | 1984 |
Visual evoked potentials and ibuprofen (Motrin) toxicity.
Topics: Aged; Color Vision Defects; Evoked Potentials, Visual; Humans; Ibuprofen; Male; Osteoarthritis; Visu | 1984 |
Renal papillary necrosis following regular consumption of non-steroidal anti-inflammatory drugs.
Topics: Aged; Anti-Inflammatory Agents; Humans; Ibuprofen; Indomethacin; Ketoprofen; Kidney Papillary Necros | 1982 |
Reintroduction of anti-inflammatory drug therapy after drug-associated gastro-intestinal disturbances.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Arthritis; Duodenal Ulcer; Female; Gastrointes | 1982 |
An update on long-term efficacy and safety with benoxaprofen.
Topics: Alkaline Phosphatase; Anemia; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Aspirin; Humans; Ibup | 1982 |
Non-steroidals ineffective in OA.
Topics: Humans; Ibuprofen; Osteoarthritis; Placebos; Pyrroles; Tolmetin | 1982 |
Symptomatic osteoarthritis in the elderly: a comparative study of sulindac and ibuprofen.
Topics: Aged; Female; Hip Joint; Humans; Ibuprofen; Indenes; Knee Joint; Male; Osteoarthritis; Sulindac | 1982 |
Osteoarthritis and non-steroidal and anti-inflammatory drugs: a multi-centre comparative study.
Topics: Aged; Diclofenac; Female; Hip Joint; Humans; Ibuprofen; Indenes; Knee Joint; Male; Naproxen; Osteoar | 1982 |
The effect of ibuprofen on the thickening, stiffening and development of degenerative changes in the rabbit knee following immobilization.
Topics: Animals; Hindlimb; Ibuprofen; Immobilization; Joints; Movement; Osteoarthritis; Rabbits | 1980 |
Exercise-induced acute renal failure associated with ibuprofen, hydrochlorothiazide, and triamterene.
Topics: Acute Kidney Injury; Catecholamines; Cytokines; Eicosanoids; Hormones; Hydrochlorothiazide; Hyperten | 1995 |
When Goody's Powder is not so good.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Heart Failure; Humans; Ibuprofen; Knee Joint; Male; N | 1996 |
High-performance thin-layer chromatographic determination of ibuprofen in plasma.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure Liquid; Chromatography | 1997 |
Anti-inflammatory activity of chondroitin sulfate.
Topics: Administration, Oral; Aged; Animals; Anti-Inflammatory Agents; Chondroitin Sulfates; Feces; Female; | 1998 |
How much faith can we have in pharmacoeconomic analyses?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials as Topic; Cost-Benefit Analysis; | 1994 |
Nabumetone in elderly patients with osteoarthritis: economic benefits versus ibuprofen alone or ibuprofen plus misoprostol.
Topics: Aged; Butanones; Cost-Benefit Analysis; Direct Service Costs; Drug Therapy, Combination; Gastrointes | 1994 |
Preference for nonsteroidal antiinflammatory drugs versus acetaminophen and concomitant use of both types of drugs in patients with osteoarthritis.
Topics: Acetaminophen; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Data Collect | 2000 |
Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Cardiovascular Diseases; Clinical T | 2002 |
Gastrointestinal medications and procedures in osteoarthritis patients treated with rofecoxib compared with nonselective NSAIDs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials | 2001 |
A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Butanones; Clinical Trials, Phase II as Topic; Clinic | 2002 |
Trends in medication use for osteoarthritis treatment.
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Butanones; Drug Utilization; | 2002 |
Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arthritis; Arthritis, Rheumatoid; Celecoxib; Cyclooxygenase | 2002 |
Benorylate versus ibuprofen in the treatment of osteoarthritis.
Topics: Consumer Behavior; Female; Humans; Ibuprofen; Male; Osteoarthritis; Salicylates | 1978 |
[Therapeutic effectiveness and tolerability of p-isobutylphenylpropionate of lysine, in parenteral administration, in subjects with hyperalgic forms of rheumatic arthropathy].
Topics: Adult; Aged; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Back Pain; Brachial Plexus Neuritis; F | 1979 |
[Lysine p-isobutyl-phenylpropionate in articular and extra-articular osteoarthritis].
Topics: Adult; Aged; Anti-Inflammatory Agents; Drug Evaluation; Drug Tolerance; Female; Hip Joint; Humans; I | 1979 |
[Gastrointestinal hemorrhage during treatment with ibuprofen (Brufen)].
Topics: Aged; Aspirin; Drug Interactions; Female; Gastrointestinal Hemorrhage; Humans; Ibuprofen; Male; Midd | 1977 |
Coombs'-positive hemolytic anemia and ibuprofen.
Topics: Aged; Anemia, Hemolytic, Autoimmune; Azo Compounds; Complement C3; Coombs Test; Humans; Ibuprofen; I | 1979 |
Nonsteroidal anti-inflammatory drugs.
Topics: Arthritis, Rheumatoid; Humans; Ibuprofen; Osteoarthritis; Phenylpropionates | 1976 |
Rheumatic diseases. 2. Therapeutic considerations.
Topics: Adrenal Cortex Hormones; Arthritis, Rheumatoid; Aspirin; Calcinosis; Carpal Tunnel Syndrome; Colchic | 1976 |
The aging skeleton. Osteoporosis and degenerative arthritis.
Topics: Age Factors; Aged; Aspirin; Estrogens; Female; Fracture Fixation; Humans; Ibuprofen; Indomethacin; J | 1975 |
Evaluation of ibuprofen (Motrin). A new antirheumatic agent.
Topics: Administration, Oral; Arthritis, Rheumatoid; Aspirin; Central Nervous System; Digestive System; Drug | 1975 |
Letter: Ibuprofen and visual function.
Topics: Aged; Arthritis, Rheumatoid; Aspirin; Eye; Female; Humans; Ibuprofen; Osteoarthritis; Phenylpropiona | 1976 |
[Ibuprofen--successful in activated arthrosis. Results of a administration study].
Topics: Arthritis, Rheumatoid; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Human | 1992 |
Clinical efficacy and tolerance of galactosoaminoglucuronoglycan sulfate in the treatment of osteoarthritis.
Topics: Adult; Aged; Female; Glycosaminoglycans; Humans; Ibuprofen; Lysine; Male; Middle Aged; Osteoarthriti | 1991 |
Non-steroidal anti-inflammatory drugs and bleeding peptic ulcer.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Duodenal Ulcer; Female; Humans; Ibuprofen; Indome | 1986 |
Multiple oral petechiae and ecchymoses in a patient with osteoarthritis.
Topics: Aged; Ecchymosis; Humans; Ibuprofen; Male; Osteoarthritis; Purpura; Purpura, Thrombocytopenic; Tongu | 1987 |
The influence of ultrasound, galvanic currents and shortwave diathermy on pain intensity in patients with osteoarthritis.
Topics: Aged; Diathermy; Electric Stimulation Therapy; Hip Joint; Humans; Ibuprofen; Knee Joint; Middle Aged | 1987 |
Bilateral ballism induced by ibuprofen in a schizophrenic patient.
Topics: Aged; Dyskinesia, Drug-Induced; Female; Humans; Ibuprofen; Osteoarthritis; Schizophrenia, Paranoid | 1987 |
Diclofenac sodium in the treatment of rheumatoid arthritis and osteoarthritis.
Topics: Arthritis, Rheumatoid; Aspirin; Diclofenac; Double-Blind Method; Female; Humans; Ibuprofen; Male; Mi | 1985 |